Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity Authors: Alex L. Roederer, Yi Cao, Kerri St. Denis, Maegan L. Sheehan, Chia Jung Li, Evan C. Lam, David J. Gregory, Mark C. Poznansky, A. John Iafrate, David H. Canaday, Stefan Gravenstein, Wilfredo F. Garcia-Beltran, Alejandro B. Balazs Published: 2024 ABSTRACT SummaryWith the onset of the COVID-19 pandemic 4 years ago, viral sequencing continues to document numerous individual mutations in the viral spike protein across many variants. To determine the ability of vaccine-mediated humoral immunity to combat continued SARS-CoV-2 evolution, we construct a comprehensive panel of pseudoviruses harboring each individual mutation spanning 4 years of the pandemic to understand the fitness cost and resistance benefits of each. These efforts identify numerous mutations that escape from vaccine-induced humoral immunity. Across 50 variants and 131 mutants we construct, we observe progressive loss of neutralization across variants, irrespective of vaccine doses, as well as increasing infectivity and ACE2 binding. Importantly, the recent XBB.1.5 booster significantly increases titers against most variants but not JN.1, KP.2, or KP.3. These findings demonstrate that variants continue to evade updated mRNA vaccines, highlighting the need for different approaches to control SARS-CoV-2 transmission. Introduction Since it was described in late 2019, SARS-CoV-2 has undergone continuous evolution. The virus originated in Wuhan, China, and was declared a global pandemic on March 11, 2020 by the World Health Organization (WHO).1,2 Since then, it has infected over 700 million people and caused nearly 7 million deaths.2,3 The first mutation to become fixed in the population, D614G, emerged in February of 2020 and was shown to be more infectious and stable than the original sequence.4,5 However, the first variant to be named, B.1.1.7 or Alpha, harbored multiple mutations and became the dominant strain in the UK, exhibiting over 50% greater infectivity than the wild type (WT).6 As the pandemic entered its second year, additional variants emerged carrying mutations in the receptor-binding domain (RBD) that enhanced transmissibility7,8 through improved ACE2 binding and exhibited viral escape from convalescent sera.9,10,11 Numerous studies in the first two years of the pandemic reported mutations including L452R,12,13 K417N/T,6,14,15 E484K,16 N501Y,17 Q677H,18,19 and P618H/R,20,21 which exhibited immune evasiveness, stronger ACE2 binding, or increased fusogenicity and infectivity. In the subsequent two years, the number of variants that have been documented has increased significantly, with mutations (predominantly in the RBD) that enable escape from vaccine-induced neutralizing antibodies and enhance transmissibility.10,22,23,24,25 An unprecedented effort to develop effective countermeasures resulted in multiple vaccines being approved by the Food and Drug Administration (FDA) in the United States, all of which were based upon the WT SARS-CoV-2 spike protein containing stabilizing mutations that were previously identified for respiratory synctial virus (RSV) and Middle East respiratory syndrome (MERS).26,27 Numerous vaccine technologies were employed, including mRNA containing lipid nanoparticles, recombinant proteins, or adenovirus-vectored vaccines28,29,30,31; however, mRNA vaccines were the most widely deployed in the United States. Clinical trials of these vaccines demonstrated remarkable efficacy to reduce COVID-19 infections, hospitalizations, and deaths.28,29,30,31 However, the emergence of the Omicron variant and declining antibody titers over time led to the recommendation of a third booster dose of mRNA vaccine by the FDA, yielding neutralizing, cross-reactive antibodies against Omicron.23,32 The emergence of variants such as BA.5 in 2022 necessitated the reformulation of vaccines,33 spurring the transition from monovalent to bivalent vaccines incorporating both WT and BA.5 spikes.34 Despite the efficacy of the original vaccines in preventing severe disease and death, their effectiveness waned against heavily mutated, highly transmissible variants such as BQ.1.1, XBB, BA.2.86, and their sub-variants.25,35,36,37 These highly evolved strains carried 34–58 total mutations within the spike protein, with 28 of these mutations in the RBD in the more recent variant JN.1. Numerous studies have highlighted vaccine evasion by individual spike mutations found in these strains, namely V445P,38,39 N460K,40 and F486 P/S,41,42,43,44 among others.16,17,21,43,45,46,47,48,49,50,51,52 In the fall of 2023, an FDA advisory committee recommended deployment of an updated monovalent mRNA vaccine encoding the XBB.1.5 spike.53 However, JN.1 and its derivatives KP.2 and KP.3 make up over 90% of COVID sequences being submitted to GISAID.54,55 We find that the latest XBB.1.5 booster enhances neutralizing activity against many variants that escaped bivalently boosted sera; however, the latest JN.1 variant remains significantly resistant to neutralization across vaccinations. To understand the impact of mutations that have arisen across the shifting vaccination landscape, we constructed a library of individual spike transgenes harboring each individual mutation found in variants of concern or interest. Using this resource, we conducted a comprehensive analysis of escape by individual mutations that emerged during the pandemic. Using a previously validated high-throughput assay,10,23,56 we measured the neutralization of pseudoviruses representing each individual mutation across a cohort of study participants who had received either the primary vaccine series (two shots) or the booster series (three shots) and were COVID naive. Furthermore, we evaluated the neutralization activity of sera from boosted individuals against all individual mutations, as well as strains harboring combinations of mutations through JN.1, totaling 220 different pseudoviruses. In addition, we profiled recombinant ACE2 binding of all 220 spike expression constructs to assess differences across individual mutants and variants. Interestingly, we find that a handful of individual mutations arising enable significant escape from boosted serum but also have reduced ACE2 binding. Remarkably, more recent variants, including BQ.1.1, XBB, and XBB.1.5, exhibit escape from boosted sera that is comparable to SARS-CoV-1 and the related pre-emergent WIV1 strain. However, sera from individuals receiving bivalent and XBB.1.5 boosters exhibited significant neutralizing activity against all variants. Despite this, variants such as EG.5, HK.3, and JN.1 exhibit substantial escape from bivalent boosted sera while KP.2 and KP.3 significantly escape XBB.1.5 boosted sera, suggesting that SARS-CoV-2 remains ahead of efforts to update vaccines. Variants not only increased escape over time, but they also drastically increased their infectivity and ACE2 binding ability. Together, these results highlight the importance of continued surveillance of SARS-CoV-2 sequence evolution and support the updating of existing vaccines. At the same time, our results also demonstrate the need to develop approaches capable of inducing broadly neutralizing humoral immunity to counter the continued evolution of SARS-CoV-2. Results Comprehensive neutralization assays with primary vaccine sera reveal regions of vulnerability within the natural mutation landscape SARS-CoV-2 has resulted in over 700 million infections and nearly 7 million deaths since it emerged in 2020.2,3 The virus, which originated in Wuhan, China, circulated for nearly a year before the variant of concern (Alpha) emerged (Figure 1A; Table S1); however, in subsequent years, numerous variants of concern and interest have been described (Figure 1B; Table S1). The mutations of each variant are highlighted on the structure of a full-length spike protein to indicate how many mutations on the WT structure each variant carries but are not meant to be the structures of the variants. One of the most globally dominant variants, Delta (B.1.617.2), was ascendant in June 2021 and harbored 8 mutations, including 2 in the RBD.9,55 However, the Omicron variant (BA.1), containing 32 spike mutations, rapidly rose to prominence after it appeared in November 2021. Variants derived from BA.1 continued to emerge resulting in the BA.5 strain harboring two additional mutations within the RBD. JN.1 then became the dominant strain globally55 and harbor 58 total spike mutations with 27 of these in the RBD.54 Impressively, the SARS-CoV-2 pandemic has now resulted in variants that are further evolved (by number of mutations) from the original Wuhan strain than other distinct coronaviruses such as RaTG1357,58 (Figure 1C), which harbors only 26 amino acid changes shown on the structure of the WT spike for reference. Over the course of the pandemic, 164 individual mutations in viral spike have arisen across variants of concern/interest up to JN.1, including several that occurred at the same position in the WT spike protein numbering (Figure 1D).Figure 1SARS-CoV-2 variants of concern harbor spike protein mutations that are enriched in the RBD(A) Scaled stacked area chart of variants emerging during the SARS-CoV-2 pandemic. Arrows denote when each vaccine was made available. Adapted from nextstrain.org. Data as of February 28, 2024.(B) Crystal structures of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) highlighting mutations found in each strain mapped onto their locations on the wild-type spike trimer. From left to right WT, Delta (B.1.617.2), Omicron (BA.1), BA.5, and JN.1 strains. Mutations highlighted for each strain are from corresponding Table S1.(C) Crystal structure of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with differences with the closely related RaTG13 coronavirus highlighted in red (front and top view) on the WT spike trimer.(D) Crystal structure of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with all 164 mutations found in variants of concern and variants of interest up to and including JN.1, mapped onto the WT spike, and colored by the number of times they have been observed in a single variant of concern or variant of interest. Red = 1, orange = 2 yellow = 3, green = 4.(E) Schematic of high-throughput neutralization assay used in these studies. SARS-CoV-2 variants of concern harbor spike protein mutations that are enriched in the RBD (A) Scaled stacked area chart of variants emerging during the SARS-CoV-2 pandemic. Arrows denote when each vaccine was made available. Adapted from nextstrain.org. Data as of February 28, 2024. (B) Crystal structures of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) highlighting mutations found in each strain mapped onto their locations on the wild-type spike trimer. From left to right WT, Delta (B.1.617.2), Omicron (BA.1), BA.5, and JN.1 strains. Mutations highlighted for each strain are from corresponding Table S1. (C) Crystal structure of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with differences with the closely related RaTG13 coronavirus highlighted in red (front and top view) on the WT spike trimer. (D) Crystal structure of pre-fusion stabilized SARS-CoV-2 spike trimer (PDB ID 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with all 164 mutations found in variants of concern and variants of interest up to and including JN.1, mapped onto the WT spike, and colored by the number of times they have been observed in a single variant of concern or variant of interest. Red = 1, orange = 2 yellow = 3, green = 4. (E) Schematic of high-throughput neutralization assay used in these studies. To investigate the effect of all individual spike variations on vaccine-induced humoral immunity, we studied a cohort of 20 COVID naive donors (as defined by nucleocapsid serum reactivity) who had received the primary vaccine series (Table S2). Sera from this group were subjected to pseudovirus-based neutralization assays that we and others have previously validated.10,23,56,60,61,62,63,64 In brief, pseudotyped lentiviral particles bearing a given SARS-CoV-2 spike protein and encoding a luciferase-expressing transgene were produced and mixed with serially diluted donor serum before ACE2-expressing target cells were added (Figure 1E). Assays were performed using pseudoviruses representing 69 differences present across 24 named variants of concern/interest up to and including Delta (Figures 2A and S1A). Variants with multiple consensus sequences such as Beta (V1–V6) are denoted as separate variants (Figure S1A). Donor serum exhibited high neutralizing activity against the Wuhan pseudovirus, with a geometric mean pseudovirus 50% neutralization titer (pNT50) of 2,962 (Figure S1B). However, individual changes in either the N-terminal domain (NTD), RBD, or other portions of the S1 region exhibited significant escape from neutralization (Figure 2B), many of which have been previously reported.14,15,16,18,19,20,21,46,47,65,66 Mutations that significantly escaped sera from the primary vaccine were found to be enriched in specific regions within the RBD and NTD (Figure 2C). Recombinant ACE2 binding to spike at the cell surface was assessed to explore the impact of individual mutations on ACE2 binding (Figure S1C). Many of the mutations that escaped the primary vaccine reduced ACE2 binding, suggesting a trade-off between viral escape and receptor binding, as was previously reported for K417N/T14,15,65 (Figure 2D). Individual mutations rarely increased ACE2 binding; however, several including ΔH69V70, D215G, D614G, and H655Y achieved statistical significance (Figure S1C). To explore the interplay between resistance and ACE2 binding, we correlated neutralization resistance to ACE2 binding and found a significant correlation between stronger ACE2 binding and neutralization resistance (Figure 2E). Despite this, a majority of mutations (57 total, 82%) decreased ACE2 binding relative to WT suggesting that variants arose to escape immunity but not necessarily to improve receptor binding. Only 7 mutations both increased ACE2 binding and were harder to neutralize, most notably D614G, indicating that, at the individual mutation level, it is difficult for the virus to optimize for both parameters simultaneously. To explore individual vaccine responses, two-way hierarchical clustering was performed across all mutations tested for each individual donor (Figure 2F). This analysis revealed that sera from naive patients receiving the primary vaccine had remarkably similar losses of neutralizing activity across the subset of mutations illustrated in Figure 2B, with more than half of all mutations being harder to neutralize than WT. Interestingly, two separate clusters of donors were observed in this cohort, with the bottom cluster having a broader overall response to individual mutations arising through the Delta strain. However, we found no correlation across time, age, or gender to account for vaccination outcomes (not shown). These results suggest that humoral responses in most individuals were focused on particular epitopes within the NTD, RBD, and the rest of S1, following the primary vaccination regimen with approximately half of these individuals generating broader responses.Figure 2Comprehensive neutralization assays with primary vaccine sera revealed regions of vulnerability within the natural mutation landscape(A) Schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below.(B) Titers (n = 2 per sample per pseudovirus) that achieve 50% of pseudovirus neutralization (pNT50) are plotted for mutants with significant escape primary vaccination regimen (2 doses of Pfizer) found in SARS-CoV-2 through Delta (1.617.2). The solid black line represents geometric mean pNT50 for reference. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit.(C) Spike structure (PDB ID: 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with mutations critical for escape from primary vaccine sera mapped onto the spike. The geometric mean pNT50 value for mutations relative to WT was log transformed into a B factor on a scale of −0.9 to 0.9.(D) Individual pseudovirus mutants that escaped primary vaccinees were measured for ACE2 binding. These values were then normalized to WT binding and log transformed. Binding was done for each mutant in technical triplicates (n = 3). Data are represented as mean ± SD (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001).(E) Neutralization titer relative to WT (average of n = 2) for primary vaccinees was plotted against ACE2 binding relative to WT (average of n = 3). Both values are log transformed, and a correlation between them was detected with p = 0.0134. Numbers of mutations and percentages in each quadrant are listed, and mutations are colored according to their location on the spike.(F) Two-way hierarchical clustering of pNT50 values of sera obtained from vaccinated donors (rows) across each variant (columns) relative to individual donor WT titer. pNT50 values are plotted in a heatmap colored according to neutralizing activity relative to WT. Donors with WT neutralizing titers at the maximum of our assay were excluded. Mutations where a significant majority of donor titers reached the limit of detection were also excluded. Clustering was performed using pheatmap package v1.0.12 in RStudio. Comprehensive neutralization assays with primary vaccine sera revealed regions of vulnerability within the natural mutation landscape (A) Schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below. (B) Titers (n = 2 per sample per pseudovirus) that achieve 50% of pseudovirus neutralization (pNT50) are plotted for mutants with significant escape primary vaccination regimen (2 doses of Pfizer) found in SARS-CoV-2 through Delta (1.617.2). The solid black line represents geometric mean pNT50 for reference. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit. (C) Spike structure (PDB ID: 6XR8,59https://doi.org/10.2210/pdb6XR8/pdb) with mutations critical for escape from primary vaccine sera mapped onto the spike. The geometric mean pNT50 value for mutations relative to WT was log transformed into a B factor on a scale of −0.9 to 0.9. (D) Individual pseudovirus mutants that escaped primary vaccinees were measured for ACE2 binding. These values were then normalized to WT binding and log transformed. Binding was done for each mutant in technical triplicates (n = 3). Data are represented as mean ± SD (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001). (E) Neutralization titer relative to WT (average of n = 2) for primary vaccinees was plotted against ACE2 binding relative to WT (average of n = 3). Both values are log transformed, and a correlation between them was detected with p = 0.0134. Numbers of mutations and percentages in each quadrant are listed, and mutations are colored according to their location on the spike. (F) Two-way hierarchical clustering of pNT50 values of sera obtained from vaccinated donors (rows) across each variant (columns) relative to individual donor WT titer. pNT50 values are plotted in a heatmap colored according to neutralizing activity relative to WT. Donors with WT neutralizing titers at the maximum of our assay were excluded. Mutations where a significant majority of donor titers reached the limit of detection were also excluded. Clustering was performed using pheatmap package v1.0.12 in RStudio. Combinations of individual RBD mutations yield neutralization resistance and impact ACE2 binding Given that variants of concern/interest harbor multiple mutations, we assessed the impact of combinations of RBD mutations focusing on the Beta and Delta variants, which both readily escaped sera from primary vaccinees. We have previously shown that the RBD region of Beta was largely responsible for escape from neutralization.10 To understand how multiple RBD mutations might coordinate to escape humoral immunity, primary vaccine sera were tested against double and triple RBD mutants (Figure 3A). Neither single mutation came close to recapitulating the neutralization resistance of the parent spike, but we did observe an additive effect for the three individual RBD mutations found in the Beta variant. Combinations of any two mutations yielded greater resistance to neutralization than single mutations, but the triple mutant exhibited nearly as much escape as the full Beta spike. In contrast to Beta, combining RBD mutations in Delta resulted in no additional reduction in pNT50, suggesting that mutations outside of RBD, likely P681R, which was highly resistant as well, appear to coordinate with L452R to drive greater escape (Figure 3B). To understand the impact that these combinations had on ACE2 binding, recombinant ACE2 staining was performed and binding relative to WT was assessed (Figures 3C and 3D). Of note, individual RBD mutations in Beta drastically reduced ACE2 binding, but combining all three significantly increased ACE2 binding (Figure 3C). In contrast, individual RBD mutations in the Delta variant exhibited modest changes in ACE2 binding; however, the combination of both exhibited significantly lower ACE2 binding than WT. Importantly, mutations outside of RBD restored ACE2-binding activity in the Delta variant, highlighting the importance of sequence context when evaluating individual mutations (Figure 3D).Figure 3Combinations of individual mutations yield neutralization resistance and variable ACE2 binding(A and B) Primary series vaccinee sera (average of n = 2) was tested via pseudovirus-based neutralization assays against combinations of RBD mutations found in the (A) Beta variant or (B) Delta strain. Each variant was compared to the wild type using a one-way ANOVA with Friedman’s test and Dunn’s multiple comparisons test. (∗ = p < 0.0332, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001).(C and D) Single, double, or triple RBD mutants for the Beta (C) and Delta (D) variants were measured for ACE2 binding. Mutants were co-transfected with a zsgreen plasmid to be expressed on the surface of cells, and ACE2 binding was measured using a fluorescently labeled recombinant ACE2 protein using median fluorescence intensity of ACE2 Alexa 647, spike-positive (green) cells. Experiments were performed in technical triplicates (n = 3). Data are represented as mean ± SD. These values were then normalized to WT binding and log transformed. ACE2 binding was compared to WT using a one-way ANOVA with Dunn’s multiple comparisons test. (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001). ∗, significantly worse ACE2 binding. Combinations of individual mutations yield neutralization resistance and variable ACE2 binding (A and B) Primary series vaccinee sera (average of n = 2) was tested via pseudovirus-based neutralization assays against combinations of RBD mutations found in the (A) Beta variant or (B) Delta strain. Each variant was compared to the wild type using a one-way ANOVA with Friedman’s test and Dunn’s multiple comparisons test. (∗ = p < 0.0332, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001). (C and D) Single, double, or triple RBD mutants for the Beta (C) and Delta (D) variants were measured for ACE2 binding. Mutants were co-transfected with a zsgreen plasmid to be expressed on the surface of cells, and ACE2 binding was measured using a fluorescently labeled recombinant ACE2 protein using median fluorescence intensity of ACE2 Alexa 647, spike-positive (green) cells. Experiments were performed in technical triplicates (n = 3). Data are represented as mean ± SD. These values were then normalized to WT binding and log transformed. ACE2 binding was compared to WT using a one-way ANOVA with Dunn’s multiple comparisons test. (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001). ∗, significantly worse ACE2 binding. mRNA booster vaccination significantly enhances neutralization of SARS-CoV-2 mutants During a significant spike in COVID-19 cases in July 2021 stemming from the Delta variant, a third mRNA booster shot consisting of the same Wuhan spike formulation as the primary series was introduced in the United States67 (Figure 4A). To measure the impact of a third mRNA administration on humoral immunity, 22 COVID-naive (by nucleocapsid test) samples from mRNA-boosted donors were subjected to neutralization assays across the same set of individual mutations reported through October 2021 (up to the Delta variant) (Figure S2A). Donors were age and WT pNT50 matched to the primary series donors (Table S3). The vast majority of mutants tested were more potently neutralized relative to the WT titer by serum from boosted donors than those who had only received the primary series (Figure S2B). Mutations that significantly escaped primary series were easier for boosted donors to neutralize, relative to WT titer (Figure 4B). However, 9 of these were still able to significantly escape boosted serum (Figure 4C), including P26S, Y453F, V1176F, and M1229I. Interestingly, some mutants, including D80A, K417N, T572I, and Q677H, exhibited disproportionately greater neutralization relative to WT, suggesting that these epitopes were preferentially targeted by booster vaccination (Figure 4D). However, boosting resulted in an overall broadening against nearly all individual mutations that had occurred through Delta (Figure 4D). Comparison between the two groups found that donors who received the booster vaccine had significantly increased neutralization activity overall (Figure 2E). Two-way hierarchical clustering was performed across all mutations tested for each individual donor (Figure S2C). Boosting greatly enhanced the breadth of neutralizing titers relative to WT for all but 1 of the 13 donors we analyzed (Figure S2C). Taken together, our results confirm previous reports that booster vaccination increases breadth against SARS-CoV-2 variants.23,68,69,70,71Figure 4mRNA boosters significantly enhance neutralization of SARS-CoV-2 mutants(A) (Top) schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below.(B) (Bottom) primary or boosted pNT50 (n = 2) for donors across each variant was normalized to geometric mean titer across all donors for WT and log transformed. Length of each vertical line illustrates pNT50 change.(C) Titers (n = 2 per sample per pseudovirus) that achieve 50% of pseudovirus neutralization (pNT50) are plotted for mutants with significant escape boosted vaccination regimen found in SARS-CoV-2 through Delta (1.617.2). The solid black line represents geometric mean pNT50 for reference. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit.(D) Log-transformed pNT50 geometric mean values (average of n = 2) for each variant relative to WT for primary series were plotted against matching boosted values. Linear regression (R2 = 0.5109; slope = −0.098; p < 0.001). Mutations that were escaped for primary vaccinees only or primary and boosted vaccinees are indicated. Labeled mutations are those that had the biggest change in pNT50 value relative to WT for boosted donors. Mutations that were escaped from primary series are highlighted in purple, and those that escape primary and boosted are pink.(E) Log-transformed pNT50 geometric mean values (average of n = 2) for each variant relative to WT colored according to their location in the spike protein comparing primary to boosted vaccinee sera. Statistics represent Wilcoxon two-tailed paired, nonparametric t test with ∗∗∗∗p < 0.0001. Selected RBD mutations from the delta and beta strains connected with lines showing their respective values for primary or boosted donor serum. mRNA boosters significantly enhance neutralization of SARS-CoV-2 mutants (A) (Top) schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below. (B) (Bottom) primary or boosted pNT50 (n = 2) for donors across each variant was normalized to geometric mean titer across all donors for WT and log transformed. Length of each vertical line illustrates pNT50 change. (C) Titers (n = 2 per sample per pseudovirus) that achieve 50% of pseudovirus neutralization (pNT50) are plotted for mutants with significant escape boosted vaccination regimen found in SARS-CoV-2 through Delta (1.617.2). The solid black line represents geometric mean pNT50 for reference. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit. (D) Log-transformed pNT50 geometric mean values (average of n = 2) for each variant relative to WT for primary series were plotted against matching boosted values. Linear regression (R2 = 0.5109; slope = −0.098; p < 0.001). Mutations that were escaped for primary vaccinees only or primary and boosted vaccinees are indicated. Labeled mutations are those that had the biggest change in pNT50 value relative to WT for boosted donors. Mutations that were escaped from primary series are highlighted in purple, and those that escape primary and boosted are pink. (E) Log-transformed pNT50 geometric mean values (average of n = 2) for each variant relative to WT colored according to their location in the spike protein comparing primary to boosted vaccinee sera. Statistics represent Wilcoxon two-tailed paired, nonparametric t test with ∗∗∗∗p < 0.0001. Selected RBD mutations from the delta and beta strains connected with lines showing their respective values for primary or boosted donor serum. Individual Omicron mutants reveal sites of resistance that are also found in more recent strains, against boosted sera In November of 2021, a SARS-CoV-2 variant harboring an unusually large number of mutations was identified in South Africa.72 This variant of concern, designated Omicron (BA.1), contained 59 mutations in its genome, 32 of which were in the spike protein, with 15 in the RBD. A number of heavily mutated, highly transmissible variants have descended from BA.1 since this time.35,73,74 Neutralization assays were performed to assess whether boosted sera exhibited improved activity against 132 more recent mutations across 48 named variants (Figures S3A and 5A). While sera from individuals receiving a third mRNA booster vaccine were able to neutralize most mutants (Figure S3B), spike mutations V445P, N460K, and F486P exhibited the highest fold decrease in pNT50 (Figure 5B), which others have reported as critical for escape.40,41,42,43,44,75 Notably, many other mutations significantly escaped boosted serum including V213E, insR214-EPE, G252V, G339D, G339H, L368I, and Y453F (Figure 5B). Despite their antibody escape, most of these mutations also exhibited reduced ACE2 binding when analyzed individually (Figure 5C). These results further support the concept of a trade-off between binding and escape with the exception of N460K, which was previously reported to increase both ACE2 binding and escape.40 Across the full set of mutations arising since the beginning of the pandemic, numerous individual mutations escaped from mRNA-boosted serum samples (Figure S5B). Most of these also decreased ACE2 binding relative to WT, except for N460K, D614G, and H655Y, which significantly increased binding (Figure S3C). The relationship between ACE2 binding and boosted serum neutralization resistance was significantly correlated (p = 0.0002); however, 88% of mutants decreased ACE2 binding relative to WT (Figure 5D). This suggests that combinations of individual mutations were necessary to achieve both increased ACE2 binding and neutralization resistance. However, we identified 7 individual mutants that increased both ACE2 binding and escape, some of which had been previously reported including S477N,76,77 L452R,12,13 and D614G.4,5,78Figure 5Individual Omicron variants reveal sites of resistance that are observed in more recent strains to significantly escape from boosted sera(A) Schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below.(B) pNT50 are plotted for all individual spike mutations occurring through XBB.1.16 variant with significant escape from 22 COVID naive boosted donors (n = 2 per sample per pseudovirus). The solid black line indicates the geometric mean of the titers against each pseudovirus. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit.(C) Individual pseudovirus mutants that escaped boosted vaccinees were measured for ACE2 binding. These values were then normalized to WT binding and log transformed. All experiments were performed in technical triplicates (n = 3). ∗, significantly worse ACE2 binding. Data are represented as mean ± SD (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001).(D) Neutralization titer relative to WT (average of n = 2) for boosted vaccinees was plotted against ACE2 binding relative to WT (average of n = 3). Both values are log transformed, and a correlation between them was detected with p = 0.0002. Numbers of mutations and percentages in each quadrant are listed, and mutations are colored according to their location on the spike.(E) ACE binding relative to WT and infectivity relative to WT were plotted against each other. Each variant was tested in technical triplicates (average of n = 3). ACE2 binding and infectivity were assessed for correlation using a nonparametric two-tailed spearman correlation. p = 0.33. Individual Omicron variants reveal sites of resistance that are observed in more recent strains to significantly escape from boosted sera (A) Schematic illustrating the time period from which variants were selected and the vaccinee sera to be tested below. (B) pNT50 are plotted for all individual spike mutations occurring through XBB.1.16 variant with significant escape from 22 COVID naive boosted donors (n = 2 per sample per pseudovirus). The solid black line indicates the geometric mean of the titers against each pseudovirus. The following abbreviations are used: NTD, N-terminal domain; RBD, receptor binding domain; S1, S1 subunit; S2, S2 subunit. (C) Individual pseudovirus mutants that escaped boosted vaccinees were measured for ACE2 binding. These values were then normalized to WT binding and log transformed. All experiments were performed in technical triplicates (n = 3). ∗, significantly worse ACE2 binding. Data are represented as mean ± SD (∗p < 0.0332, ∗∗p < 0.0021, ∗∗∗p < 0.0002, ∗∗∗∗p < 0.0001). (D) Neutralization titer relative to WT (average of n = 2) for boosted vaccinees was plotted against ACE2 binding relative to WT (average of n = 3). Both values are log transformed, and a correlation between them was detected with p = 0.0002. Numbers of mutations and percentages in each quadrant are listed, and mutations are colored according to their location on the spike. (E) ACE binding relative to WT and infectivity relative to WT were plotted against each other. Each variant was tested in technical triplicates (average of n = 3). ACE2 binding and infectivity were assessed for correlation using a nonparametric two-tailed spearman correlation. p = 0.33. As compared to mutations that emerged in variants up to and including Delta, those emerging from Omicron onwards exhibited significantly less neutralization by boosted sera (p = 0.0021) (Figure S4A). Interestingly, individual mutations post-Delta were also significantly worse at binding to ACE2 vs. mutations pre-Delta (Figure S4B). Mapping these mutations onto the structure of the SARS-CoV-2 spike revealed that mutations appearing post-Delta were largely concentrated at the apex of the spike as well as parts of the NTD (Figure S4C). Neutralization titers of boosted sera against a panel of strains throughout the pandemic showed a 5-fold decrease in pNT50 value beginning with BA.1, further decreasing to 104-fold for the most escaped among them, BQ.1.1.22 (Figure S5A). In contrast to individual mutations, all strains exhibited improved ACE2 binding relative to the WT isolate, with Alpha and XBB descendants having the most significant increase (Figure S5B). When comparing neutralizing titer to ACE2 binding, all strains became harder to neutralize and better at binding to ACE2, with variants clustering on the plot by sequence similarity, but these trends were not significant (Figure 5E). Bivalent and XBB.1.5 boosters markedly improve neutralization against recent variants in a nursing home cohort During a surge in cases, largely attributed to the BA.5 variant, bivalent mRNA vaccines encoding both WT and BA.5 spike sequences were approved for use in the United States in August of 2022.33,79 With the recombination of spikes producing XBB and sub-variants, and the waning immunity of bivalent vaccination against these variants,80,81 a reformulated vaccine encoding only the XBB.1.5 spike sequence was recommended for use in September 2023.82,83 We obtained longitudinal samples from 29 nursing home residents (median of 72 years old) and 7 health care workers (median age 60) who received either three or four WT mRNA vaccines followed by a bivalent booster and an XBB.1.5 booster (Table S4). To measure the impact of each vaccine administration, longitudinal serum samples, collected 2–4 weeks after vaccination, were tested against variants previously found to escape boosted sera, or which were dominant variants for more than a month (Figure 6A). While there was a clear trend of increased neutralizing activity with each successive vaccination, only modest differences were observed between the 3rd and 4th WT mRNA boost (Figure 6B). Bivalent vaccines improved pseudovirus neutralization titers after BA.5, though the activity against these variants was still significantly lower than WT (Figure S6A). While significantly improving titers against all variants up until JN.1, KP.2 and KP.3 showed significant escape from the XBB.1.5 boosted sera with KP.3 exhibiting 12.8-fold reduction in neutralizing titer. (Figure S6B). Overall, we observed increasing neutralization titers against all pseudoviruses tested relative to WT in the same cohort across each successive vaccination from WT booster to bivalent booster, and finally to XBB.1.5 booster (Figure 6C). We also observed a significant decline in neutralization activity across variants that arose across time for WT and bivalent boosters but no significant decline across variants following XBB.1.5 booster vaccination (Figure 6D). Two-way hierarchical clustering was performed on matched donors at the boosted time point to understand the effect of additional boosters against these variants (Figure 6E). Donors separated into two clusters after receiving a 3rd WT booster, one with broader neutralizing activity and another with lower activity against BQ.1.1.22 and later strains. However, the distinction between these two clusters was largely attenuated with each successive administration of bivalent and XBB1.5 boosters. Taken together, these observations suggest that bivalent and XBB.1.5 boosters substantially improve the neutralization activity of sera against highly mutated variants.Figure 6Updated COVID boosters improve neutralization against dominant variants throughout the pandemic(A) Schematic illustrating the variants and vaccinee sera to be tested below.(B) Geometric mean pNT50 values of longitudinal serum samples (average of n = 2) over the course of CDC-recommended vaccination schedule against each variant. Strains are plotted in the order in time that they first appear in GISAID.(C) pNT50 of individual serum samples (average of n = 2) were normalized to geometric mean titer across all donors for WT and log transformed. Longitudinal samples from donors after WT, bivalent, or XBB.1.5 boosters are plotted. Length of each vertical line illustrates pNT50 change.(D) Log-transformed pNT50 geometric mean values (average of n = 2) relative to WT for donor sera against variants of concern through JN.1 plotted against the date of first submission to GISAID. Solid lines represent linear regressions for WT booster (R2 = 0.63, slope = −0.298, p = 0.002), bivalent booster (R2 = 0.57, slope = −0.24, p = 0.0018), and XBB.1.5 booster titers (R2 = 0.31, slope = −0.133, p = 0.0379).(E) One-way hierarchical clustering of pNT50 values of sera obtained from boosted donors (rows) across each variant of concern (columns) relative to individual donor WT titer. Heatmaps maintaining clustering order of rows across bivalent and XBB.1.5 boosters are plotted to the right. pNT50 values are plotted in heatmaps colored according to neutralizing activity relative to WT. Clustering was performed using pheatmap package v1.0.12 in RStudio. Updated COVID boosters improve neutralization against dominant variants throughout the pandemic (A) Schematic illustrating the variants and vaccinee sera to be tested below. (B) Geometric mean pNT50 values of longitudinal serum samples (average of n = 2) over the course of CDC-recommended vaccination schedule against each variant. Strains are plotted in the order in time that they first appear in GISAID. (C) pNT50 of individual serum samples (average of n = 2) were normalized to geometric mean titer across all donors for WT and log transformed. Longitudinal samples from donors after WT, bivalent, or XBB.1.5 boosters are plotted. Length of each vertical line illustrates pNT50 change. (D) Log-transformed pNT50 geometric mean values (average of n = 2) relative to WT for donor sera against variants of concern through JN.1 plotted against the date of first submission to GISAID. Solid lines represent linear regressions for WT booster (R2 = 0.63, slope = −0.298, p = 0.002), bivalent booster (R2 = 0.57, slope = −0.24, p = 0.0018), and XBB.1.5 booster titers (R2 = 0.31, slope = −0.133, p = 0.0379). (E) One-way hierarchical clustering of pNT50 values of sera obtained from boosted donors (rows) across each variant of concern (columns) relative to individual donor WT titer. Heatmaps maintaining clustering order of rows across bivalent and XBB.1.5 boosters are plotted to the right. pNT50 values are plotted in heatmaps colored according to neutralizing activity relative to WT. Clustering was performed using pheatmap package v1.0.12 in RStudio. SARS-CoV-2 variants of concern display increased ACE2 binding and infectivity over time To compare variants of concern that were previously dominant or had escaped vaccines, we assessed ACE2 binding and the efficiency of viral entry mediated by the spike protein. All variants exhibited greater ACE2 binding than WT, but only strains arising after BQ.1.1.22 showed significant differences (Figure 7A). Notably, BA.2.86 and its descendant JN.1 had the strongest overall ACE2 binding, which was nearly 5-fold higher than WT. When analyzed relative to the date when each variant emerged, we found a significant correlation (p = 0.0047) between ACE2 binding and time, indicating that variants of concern increased their ACE2 binding over the course of the pandemic (Figure 7B).Figure 7SARS-CoV-2 variants of concern have accumulated spike mutations increasing their infectivity and ACE2 binding over time(A) Individual pseudovirus mutants were measured for ACE2 binding. All experiments were done in technical triplicates (n = 3). These values were then normalized to WT binding and compared to SARS-CoV-2 using a one-way ANOVA with Holm-Sidak correction for multiple comparisons. (∗ = p < 0.033, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001). Data are represented as mean ± SD.(B) ACE2 binding values (average of n = 3) plotted for each variant relative to the time it was first submitted to the GISAID database. A simple linear regression was performed with R2 = 0.53, p = 0.0047, slope = 0.707.(C) Pseudovirus infectivity (defined as infectious units per genome copy) was normalized to WT infectivity for each variant spike across technical triplicates (n = 3). Pseudovirus infectivity relative to WT was measured for major SARS-CoV-2 variants by calculating fold change in slope of linear regressions fit across known dilutions. Bars and error bars depict mean and standard error of the mean. Each pseudovirus was compared to SARS-CoV-2 wild type using a one-way ANOVA with Holm-Sidak correction for multiple comparisons. (∗ = p < 0.033, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001). Data are represented as mean ± SD.(D) Pseudovirus infectivity values (average of n = 3) plotted for each variant relative to the time it was first submitted to the GISAID database. A simple linear regression was performed with R2 = 0.42, p = 0.0179, and slope = 5.89. SARS-CoV-2 variants of concern have accumulated spike mutations increasing their infectivity and ACE2 binding over time (A) Individual pseudovirus mutants were measured for ACE2 binding. All experiments were done in technical triplicates (n = 3). These values were then normalized to WT binding and compared to SARS-CoV-2 using a one-way ANOVA with Holm-Sidak correction for multiple comparisons. (∗ = p < 0.033, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001). Data are represented as mean ± SD. (B) ACE2 binding values (average of n = 3) plotted for each variant relative to the time it was first submitted to the GISAID database. A simple linear regression was performed with R2 = 0.53, p = 0.0047, slope = 0.707. (C) Pseudovirus infectivity (defined as infectious units per genome copy) was normalized to WT infectivity for each variant spike across technical triplicates (n = 3). Pseudovirus infectivity relative to WT was measured for major SARS-CoV-2 variants by calculating fold change in slope of linear regressions fit across known dilutions. Bars and error bars depict mean and standard error of the mean. Each pseudovirus was compared to SARS-CoV-2 wild type using a one-way ANOVA with Holm-Sidak correction for multiple comparisons. (∗ = p < 0.033, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001). Data are represented as mean ± SD. (D) Pseudovirus infectivity values (average of n = 3) plotted for each variant relative to the time it was first submitted to the GISAID database. A simple linear regression was performed with R2 = 0.42, p = 0.0179, and slope = 5.89. To determine the ability of each spike to mediate viral entry into target cells expressing ACE2, we compared the rate of pseudovirus transduction over a range of concentrations (Figure S7A). We found that spikes ranging from BA.5 to HK.3 were significantly better at entering cells, mediating up to 30-fold more efficient cell entry than WT (Figure 7C). Notably, the highly mutated BA.2.86 spike was less efficient than preceding variants, but its descendant (JN.1) displayed 15-fold higher efficiency of cell entry than WT. Although we found no significant correlation between ACE2 binding and cell entry efficiency (Figure S7B), we observed that entry efficiency was significantly (p = 0.0179) correlated with time of variant emergence, indicating that variants of concern have become more efficient at cell entry over the course of the pandemic (Figure 7D). Discussion Although the COVID-19 pandemic declaration was ended by the WHO in May 2023, SARS-CoV-2 continues to transmit globally in the form of highly mutated variants. We sought to understand how the constellation of mutations that have appeared since the beginning of the pandemic were impacted by the changing landscape of humoral immunity driven by updated vaccines. To this end, we determined the neutralization potency of patient sera against pseudoviruses representing 131 individual mutations from 50 named strains of SARS-CoV-2. Spike expression plasmids encoding each individual variant or strain have been deposited in a public repository that will make this resource freely available. Our study utilized this collection to characterize serum samples from COVID-naive donors who received a primary vaccination series, defined as either two shots of the Pfizer28 or Moderna29 mRNA vaccines or a third mRNA booster dose. We also analyzed longitudinal samples from a cohort consisting primarily of nursing home residents, taken after each successive vaccination. These individuals received up to a total of six mRNA vaccines, including the recent XBB.1.5 booster. We find that sera from COVID-naive donors who received a primary vaccine series were especially vulnerable to individual mutations across multiple regions of the spike protein, including NTD, RBD, the C-terminal region of S1, and the C terminus of S2. Numerous individual mutations within the RBD resulted in significant escape from primary vaccination, many of which have been previously reported.14,15,65 A majority of the single mutants through the Delta variant (82%) tested also exhibited lower ACE2 binding. This could be attributed to the expression at the surface of cells; however, most mutants expressed at a similar level to the WT virus. In agreement with others,4,78,84,85 we found that D614G and H655Y conferred the greatest increase in ACE2 binding relative to the WT spike. D215G and ΔH69V70 mutants also increased ACE2 binding. Contrasting to the literature,86 we observed that N501Y had significantly lower ACE2 binding relative to the WT. This difference could be attributed to a slightly lower expression of the N501Y mutant; however, most experiments have done binding with recombinantly expressed RBD while ours is done on the whole spike at the surface of the cell, which may explain this difference. Overall, our ACE2 binding data predominately agrees with what have been published. Notably, several mutants, including Q52R, L452R, S477N, T572I, D614G, H655Y, and H1101D, yielded both increased ACE2 binding and decreased neutralization. Specifically, three RBD mutations from the Beta variant (K417N, E484K, and N501Y) and two mutations from the Delta variant (L452R and P681R) substantially lowered the neutralization activity of sera from primary donors, in line with what others have observed.12,13,14,15,17,20,21,46,65 The difference between the RBD double and triple mutants and the parent variants is likely due to the critical D614G mutation seen in all variants as well as P681R for Delta. Additionally, combinations of mutations had surprising effects on ACE2 binding, with the Beta triple-mutant RBD significantly increasing ACE2 binding in agreement with others87 while the Delta double-mutant RBD significantly decreased ACE2 binding. Notably, the complete Delta strain had significantly higher ACE2 binding, suggesting that other mutations within Delta may have contributed to this difference and that the mutations are context dependent in their influence on ACE2 binding. Including the D614G and P681R mutant along with the RBD mutants would likely contribute to the increased ACE2 binding of the Delta variant. A third mRNA booster dose exhibited significantly improved neutralization across many, but not all, of the individual mutants we tested. Fewer single mutations from Delta or earlier variants were able to significantly escape boosted serum, although there was still significant escape by D253G, L452R, S477N, Q677P, and P681R mutants, which have been previously characterized.12,13,18,19,20,21,47,76,77 P26S, Y453F, V1176F, and M1229I mutants also significantly escaped boosted donor serum. Moreover, boosting disproportionately increased titers against specific key escape mutations across the spike including D80A, K417N, T572I, and Q677H. Recent publications have suggested that existing antibodies influence the outcome of vaccination by lowering the activation threshold for B cells to allow lower-affinity clones to participate as well as epitope masking to enable responses to previously ignored targets.70 Although boosting resulted in substantially greater breadth of neutralization against more recent strains, we observed a distinct loss of activity for boosted sera beginning with the emergence of the BQ.1.1 variant. Interestingly, this appeared to be largely driven by RBD and NTD mutations at positions 213, 445, 460, and 486, which have been retained in all variants since XBB. Interestingly, these four mutations achieved neutralization resistance without the loss of ACE2 binding in our assay. Moreover, mutations that appear after the Delta variant mostly reduced ACE2 binding aside from the previously reported N460K.40 In agreement with others,87,88,89,90 when we measured variant binding to ACE2, all variants had increased binding relative to the WT. Significantly, this finding indicates that mutations coordinate together in the context of each variant backbone, which could explain why most single mutants decreased ACE2 binding in our assays. More work needs to be done to understand mutant binding to ACE2 in the context of each variant rather than in the WT plasmid backbone. In response to the rapid emergence of SARS-CoV-2 variants, the vaccine formulation was twice updated, first to deliver a bivalent immunogen containing spike proteins from the WT and BA.4/BA.5 strains91,92 and then again to deliver a monovalent XBB.1.5 spike sequence.82,83 We found that bivalent booster results in neutralizing activity comparable to WT for variants BA.5 and earlier, while also improving activity against BQ.1.1 and later variants. However, these later variants still significantly escaped bivalent booster vaccination and had increased ACE2 binding. In contrast, we found that the XBB.1.5 booster results in substantial neutralization potency against later variants and only saw significant escape against Beta and the more recent JN.1 variant. In addition to mediating escape from vaccine sera, we found that spike mutations also contribute significantly to the ability of pseudovirus to infect cells and bind ACE2, suggesting that viral evolution is optimizing antibody escape, receptor binding, and viral entry simultaneously. We found that spikes from variants post-BA.1 produced pseudoviruses that were up to 30-fold better at transducing target cells than WT, suggesting that WT SARS-CoV-2 spike was not optimally configured for ACE2-dependent viral entry. Additionally, we found that variants exhibited up to 5-fold better ACE2 binding by spikes expressed on the surface of cells, although ACE2 binding and infectivity were not significantly correlated despite there being a general trend toward better receptor binding and pseudovirus entry. Our comprehensive study demonstrates that individuals receiving the full mRNA vaccination regimen, including the XBB.1.5 booster, have maximally effective neutralizing activity against recent strains of SARS-CoV-2. However, despite improvements mediated by XBB.1.5 boosters against more recently emerging strains, there is still escape, particularly by the latest JN.1 descendants KP.2 and KP.3. Surprisingly, the beta variant was also able to significantly escape both bivalent- and XBB.1.5-boosted donors. Notably, the mutations from the beta variant not seen in later variants that significantly escaped include L18F, D80A, D215G, del242-244, and A701V. These results indicate that there still exists a risk of a previous variant reemerging, although likely with a lower fitness than the current variants. These results highlight the ongoing challenge presented by continued evolution of SARS-CoV-2, which has outpaced attempts to update vaccines. Our findings support the development of vaccine and prevention modalities capable of eliciting broad protection against future variants/outbreaks. Of note, a number of monoclonal antibodies have been described that target highly conserved epitopes such as the stem helix93,94,95,96 or fusion peptide,97,98,99,100 which are capable of neutralizing across the entire Coronaviridae family. Next-generation vaccines that exploit these and other sites of vulnerability across coronaviruses will likely be necessary to combat the ongoing evolution of SARS-CoV-2 and may help prevent future pandemics. Limitations of the study While numerous prior studies have shown that neutralization activity against pseudoviruses is well correlated to replication competent SARS-CoV-2,60,61,62,63,64 it is possible that the mutations in the more recent variant spike proteins may cause them to behave differently than previously tested variants. In addition, while we confirmed that ACE2 expression is required for infection of 293T cells, natural target cells in the respiratory tract may express alternative receptors or attachment factors that facilitate infection and are not adequately modeled in our system. The study is limited to the evaluation of serum neutralizing antibodies to the spike protein for our pseudovirus neutralization assay and does not take into account neutralizing antibodies to other proteins including the N and M proteins. We also only assessed mutations in the context of the WT spike as a backbone, and there may be substantial differences in ACE2 binding of individual mutations in the context of other variant backbones such as BA.5 or XBB.1.5. Furthermore, it is possible that expression of spike at the cell surface can have an impact on ACE2 binding although most of our single mutants expressed at levels similar to the WT spike. Moreover, when assessing combinations of mutations, we only included combinations of RBD mutations within the Beta and Delta variants and did not directly test these with the addition of the D614G mutant. Given that this was the first mutation made by the virus, our study of these combinations is limited by the omission of these and could be considered to not accurately represent the variants. However, our goal was to assess the effects of the combinations of RBD mutations in the context of the WT backbone, and as such, we saw that the combinations of RBD mutants almost completely recapitulated what was seen in the full variant. Additionally, our infectivity studies only take into account the infectivity of spike mutations, not mutations in other proteins that contribute to viral infectivity. Furthermore, we did not assess other antibody-mediated functions such as complement deposition, antibody-dependent cellular cytotoxicity, or antibody-dependent cellular phagocytosis, which may contribute to protection even in the absence of neutralizing antibodies. Nor did we assess the role of vaccine-elicited cellular immune responses mediated by T cells and natural killer cells, which are likely to play a key role in disease prevention for vaccine recipients. Another limitation of the study is that the primary and boosted cohorts were COVID naive and therefore could not account for the impact of hybrid immunity. Our goal was to deeply profile the effect of vaccination on humoral immunity to COVID, so we purposefully excluded any donors that previously tested positive for COVID. For the nursing home cohort, these donors do have a COVID history, and we cannot rule out that this history has contributed to their neutralizing activity over time as they were infected between or before vaccination. We included this cohort to take a bird’s eye view of all strains throughout the entire pandemic. Resource availability Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by Alejandro Balazs (abalazs@mgh.harvard.edu). Materials availability Plasmids generated in this study are available through Addgene. Recombinant proteins and antibodies are available from their respective sources. Data and code availability This study did not generate sequence data. Data generated in the current study (including neutralization measurements and flow cytometric files) have not been deposited in a public repository but are available from the corresponding author upon request. The code used to generate the clustered heatmaps can be made available from the corresponding author upon request. Any additional information required to reanalyze the data reported in this work paper is available from the lead contact upon request. Acknowledgments We wish to thank Michael Farzan, PhD, for providing ACE2-expressing 293T cells. This work was supported by the Peter and Ann Lambertus Family Foundation. A.B.B. was supported by 10.13039/100000060NIAID R01s AI174875 and AI174276, the NIDA Avenir New Innovator Award DP2DA040254, the NIDA Avant-Garde Award 1DP1DA060607, a 10.13039/100020366Massachusetts Consortium on Pathogen Readiness grant, CDC subcontract 200-2016-91773-T.O.2, and a grant from 10.13039/100016302Coalition for Epidemic Preparedness Innovations. Author contributions Conceptualization: A.L.R., Y.C., W.F.G.-B., and A.B.B. Methodology: A.L.R., Y.C., K.S.D., M.L.S., and E.C.L. Samples: D.J.G., M.C.P., A.J.I., D.H.C., S.G., and W.F.G.-B. Investigation: A.L.R., Y.C., C.J.L., K.S.D., M.L.S., and E.C.L. Data curation: A.L.R., Y.C., K.S.D., and M.L.S. Writing – original draft: A.L.R. Writing – reviewing and editing: A.L.R., Y.C., and A.B.B. edited the paper with input from co-authors. Declaration of interests A.B.B. is a founder of Cure Systems LLC. STAR★Methods Key resources table REAGENT or RESOURCESOURCEIDENTIFIERBacterial and virus strainsDH5α Zymo-Competent E. coliZymoCat# T3009Chemicals, peptides, and recombinant proteinsPhosphate buffered saline (PBS)CorningCat# 21-031-CVDulbecco’s modified eagle medium (DMEM)CorningCat# 10-013-CVFetal bovine serum (FBS)VWRCat# 89510-186Paraformaldehyde Solution, 4% in PBS, Affymetrix/USB™Fisher ScientificCat# AAJ19943K2Penicillin/streptomycinCorningCat# 30-002-CIPolyethylenimine 25K MW, linearPolysciences IncCat# 23966PuromycinSigmaCat# P8833-10MGATPSigmaCat# A2383-5GMagnesium chlorideBDHCat# BDH9244-500GMagnesium sulfateBDHCat# BDH9246-500GDithiothreitol (DTT)VWRCat# 97061-338D-luciferinGold BioCat# LUCK-2GEDTASigmaCat# 03690-100MLTriton X-100FisherCat# BP151-500PolybreneSigmaCat# H9268-5GqScript XLT 1-Step RT-qPCR ToughMix, Low-ROXQuantabioCat# 95134-500Turbo DNaseFisherCat# AM2239Recombinant Human ACE-2 His-tag Alexa Fluor® 647 ProteinR&D SystemsCat# AFR933Experimental models: Cell linesHEK293T/17 CellsATCCCat# CRL-11268293T/ACE2.MFObtained from the lab of Dr. Michael FarzanN/AOligonucleotidesLentivirus LTR qPCR Probe/56-FAM/AGC+C/i5NitInd/GG + GA/ZEN/GCTCTCTGGC/3IABkFQ/Integrated DNA TechnologyN/ALentivirus LTR qPCR 5′ Primer GGTCTCTCTIGITAGACCAGIntegrated DNA TechnologyN/ALentivirus LTR qPCR 3′ Primer TTTATTGAGGCTTAAGCAGTGGGIntegrated DNA TechnologyN/ARecombinant DNApHAGE-CMV-Luc2-IRES-ZsGreen-W (backbone)This studyAddgene Plasmid ID 164432pTwist-SARS-CoV-2 Δ18 (spike)This studyAddgene Plasmid ID 164436pTwist-SARS-CoV-2 Δ18 B.1.617.2v1 (spike)This studyAddgene Plasmid ID 179905pTwist-SARS-CoV-2 Δ18 B.1.351v2 (spike)This studyAddgene Plasmid ID 169463pTwist-SARS-CoV-2 Δ18 P.1 (spike)This studyAddgene Plasmid ID 173476pTwist-SARS-CoV-2 Δ18 B.1.1.529 (spike)This studyAddgene Plasmid ID 179906pTwist-SARS-CoV-2 Spike-ΔC18 A222V (GTG)This studyAddgene Plasmid ID 212329pTwist-SARS-CoV-2 Spike-ΔC18 D253G (GGC)This studyAddgene Plasmid ID 212330pTwist-SARS-CoV-2 Spike-ΔC18 E281V (GTA)This studyAddgene Plasmid ID 212331pTwist-SARS-CoV-2 Spike-ΔC18 N439K (AAA)This studyAddgene Plasmid ID 212332pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC)This studyAddgene Plasmid ID 212333pTwist-SARS-CoV-2 Spike-ΔC18 D936Y (TAT)This studyAddgene Plasmid ID 212334pTwist-SARS-CoV-2 Spike-ΔC18 L5F (TTC)This studyAddgene Plasmid ID 212335pTwist-SARS-CoV-2 Spike-ΔC18 ΔH69V70This studyAddgene Plasmid ID 212336pTwist-SARS-CoV-2 Spike-ΔC18 ΔY145This studyAddgene Plasmid ID 212337pTwist-SARS-CoV-2 Spike-ΔC18 N501Y (TAT)This studyAddgene Plasmid ID 212338pTwist-SARS-CoV-2 Spike-ΔC18 A570D (GAC)This studyAddgene Plasmid ID 212339pTwist-SARS-CoV-2 Spike-ΔC18 P681H (CAC)This studyAddgene Plasmid ID 212340pTwist-SARS-CoV-2 Spike-ΔC18 T716I (ATT)This studyAddgene Plasmid ID 212341pTwist-SARS-CoV-2 Spike-ΔC18 S982A (GCC)This studyAddgene Plasmid ID 212342pTwist-SARS-CoV-2 Spike-ΔC18 D1118H (CAC)This studyAddgene Plasmid ID 212343pTwist-SARS-CoV-2 Spike-ΔC18 D80A (GCT)This studyAddgene Plasmid ID 212344pTwist-SARS-CoV-2 Spike-ΔC18 D215G (GGT)This studyAddgene Plasmid ID 212345pTwist-SARS-CoV-2 Spike-ΔC18 L242H (CAT)This studyAddgene Plasmid ID 212346pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT)This studyAddgene Plasmid ID 212347pTwist-SARS-CoV-2 Spike-ΔC18 E484K (AAA)This studyAddgene Plasmid ID 212348pTwist-SARS-CoV-2 Spike-ΔC18 A701V (GTT)This studyAddgene Plasmid ID 212349pTwist-SARS-CoV-2 Spike-ΔC18 SAK005321 (Wrong L242H)This studyAddgene Plasmid ID 212350pTwist-SARS-CoV-2 Spike-ΔC18 V1176F (TTC)This studyAddgene Plasmid ID 212351pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) E484K (AAA)This studyAddgene Plasmid ID 212352pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) N501Y (TAT)This studyAddgene Plasmid ID 212353pTwist-SARS-CoV-2 Spike-ΔC18 E484K (AAA) N501Y (TAT)This studyAddgene Plasmid ID 212354pTwist-SARS-CoV-2 Spike-ΔC18 ΔL242-L244This studyAddgene Plasmid ID 212355pTwist-SARS-CoV-2 Spike-ΔC18 R246I (ATA)This studyAddgene Plasmid ID 212356pTwist-SARS-CoV-2 Spike-ΔC18 ΔL242-L244 + R246I (ATA)This studyAddgene Plasmid ID 212357pTwist-SARS-CoV-2 Spike-ΔC18 L18F (TTC)This studyAddgene Plasmid ID 212358pTwist-SARS-CoV-2 Spike-ΔC18 T20N (AAT)This studyAddgene Plasmid ID 212359pTwist-SARS-CoV-2 Spike-ΔC18 P26S (TCC)This studyAddgene Plasmid ID 212360pTwist-SARS-CoV-2 Spike-ΔC18 D138Y (TAT)This studyAddgene Plasmid ID 212361pTwist-SARS-CoV-2 Spike-ΔC18 R190S (AGC)This studyAddgene Plasmid ID 212362pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG)This studyAddgene Plasmid ID 212363pTwist-SARS-CoV-2 Spike-ΔC18 H655Y (TAT)This studyAddgene Plasmid ID 212364pTwist-SARS-CoV-2 Spike-ΔC18 T1027I (ATT)This studyAddgene Plasmid ID 212365pTwist-SARS-CoV-2 Spike-ΔC18 S13I (ATC)This studyAddgene Plasmid ID 2123662971 - pTwist-SARS-CoV-2 Spike-ΔC18 W152C (TGC)This studyAddgene Plasmid ID 212367pTwist-SARS-CoV-2 Spike-ΔC18 L452R (CGT)This studyAddgene Plasmid ID 212368pTwist-SARS-CoV-2 Spike-ΔC18 Y453F (TTC)This studyAddgene Plasmid ID 212369pTwist-SARS-CoV-2 Spike-ΔC18 I692V (GTA)This studyAddgene Plasmid ID 212370pTwist-SARS-CoV-2 Spike-ΔC18 M1229I (ATC)This studyAddgene Plasmid ID 212371pTwist-SARS-CoV-2 Spike-ΔC18 Danish Mink ΔFVIThis studyAddgene Plasmid ID 212372pTwist-SARS-CoV-2 Spike-ΔC18 T307I (ATA)This studyAddgene Plasmid ID 212373pTwist-SARS-CoV-2 Spike-ΔC18 T572I (ATC)This studyAddgene Plasmid ID 212374pTwist-SARS-CoV-2 Spike-ΔC18 Q239R (CGA)This studyAddgene Plasmid ID 212375pTwist-SARS-CoV-2 Spike-ΔC18 Q677H (CAT)This studyAddgene Plasmid ID 212376pTwist-SARS-CoV-2 Spike-ΔC18 T307I (ATA) T572I (ATC) D614G (GGT)This studyAddgene Plasmid ID 212377pTwist-SARS-CoV-2 Spike-ΔC18 Q239R (CGA) D614G (GGT)This studyAddgene Plasmid ID 212378pTwist-SARS-CoV-2 Spike-ΔC18 D614G (GGT) Q677H (CAT) D936Y (TAT)This studyAddgene Plasmid ID 212379pTwist-SARS-CoV-2 Spike-ΔC18 SAK006840 VOC-501Y.V2 (B.1.351v3) - No RBD MutationsThis studyAddgene Plasmid ID 212380pTwist-SARS-CoV-2 Spike-ΔC18 VOC-501Y.V2 (B.1.351) - All MutationsThis studyAddgene Plasmid ID 212381pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG) E484K (AAA)This studyAddgene Plasmid ID 212382pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG) N501Y (TAT)This studyAddgene Plasmid ID 212383pTwist-SARS-CoV-2 Spike-ΔC18 (P.1) - No RBD MutationsThis studyAddgene Plasmid ID 212384pTwist-SARS-CoV-2 Spike-ΔC18 (P.2/B.1.1.248) - No RBD MutationsThis studyAddgene Plasmid ID 212385pTwist-SARS-CoV-2 Spike-ΔC18 R683G (GGC)This studyAddgene Plasmid ID 212386pTwist-SARS-CoV-2 Spike-ΔC18 SA501.V2 (Triple RBD) R683G (GGC)This studyAddgene Plasmid ID 212387pTwist-SARS-CoV-2 Spike-ΔC18 VOC-501Y.V2 (B.1.351) - McGuire MutationsThis studyAddgene Plasmid ID 212388pTwist-SARS-CoV-2 Spike-ΔC18 SA190 VOC-501Y.V2 (B.1.351v4)This studyAddgene Plasmid ID 212389pTwist-SARS-CoV-2 Spike-ΔC18 D215H (CAT)This studyAddgene Plasmid ID 212390pTwist-SARS-CoV-2 Spike-ΔC18 SAK006879 VOC-501Y.V2 (B.1.351v5)This studyAddgene Plasmid ID 212391pTwist-SARS-CoV-2 Spike-ΔC18 A27S (TCT)This studyAddgene Plasmid ID 212392pTwist-SARS-CoV-2 Spike-ΔC18 SAK007134 VOC-501Y.V2 (B.1.351v6)This studyAddgene Plasmid ID 212393pTwist-SARS-CoV-2 Spike-ΔC18 Q52R (CGA)This studyAddgene Plasmid ID 212394pTwist-SARS-CoV-2 Spike-ΔC18 A67V (GTT)This studyAddgene Plasmid ID 212395pTwist-SARS-CoV-2 Spike-ΔC18 A67V (GTT) + ΔH69V70This studyAddgene Plasmid ID 212396pTwist-SARS-CoV-2 Spike-ΔC18 F888L (CTT)This studyAddgene Plasmid ID 212397pTwist-SARS-CoV-2 Spike-ΔC18 (B.1.525)This studyAddgene Plasmid ID 212398pTwist-SARS-CoV-2 Spike-ΔC18 (Robin)This studyAddgene Plasmid ID 212399pTwist-SARS-CoV-2 Spike-ΔC18 Q677P (CCA)This studyAddgene Plasmid ID 212400pTwist-SARS-CoV-2 Spike-ΔC18 (Pelican)This studyAddgene Plasmid ID 212401pTwist-SARS-CoV-2 Spike-ΔC18 (Yellowhammer)This studyAddgene Plasmid ID 212402pTwist-SARS-CoV-2 Spike-ΔC18 T29I (ATA)This studyAddgene Plasmid ID 212403pTwist-SARS-CoV-2 Spike-ΔC18 T572I (ATC)This studyAddgene Plasmid ID 212404pTwist-SARS-CoV-2 Spike-ΔC18 D936N (AAT)This studyAddgene Plasmid ID 212405pTwist-SARS-CoV-2 Spike-ΔC18 (Bluebird)This studyAddgene Plasmid ID 212406pTwist-SARS-CoV-2 Spike-ΔC18 T732S (AGT)This studyAddgene Plasmid ID 212407pTwist-SARS-CoV-2 Spike-ΔC18 (Quail)This studyAddgene Plasmid ID 212408pTwist-SARS-CoV-2 Spike-ΔC18 G142S (AGC)This studyAddgene Plasmid ID 212409pTwist-SARS-CoV-2 Spike-ΔC18 E180V (GTA)This studyAddgene Plasmid ID 212410pTwist-SARS-CoV-2 Spike-ΔC18 (Mockingbird)This studyAddgene Plasmid ID 212411pTwist-SARS-CoV-2 Spike-ΔC18 (P.1) Triple RBDThis studyAddgene Plasmid ID 212412pTwist-SARS-CoV-2 Spike-ΔC18 T95I (ATA)This studyAddgene Plasmid ID 212413pTwist-SARS-CoV-2 Spike-ΔC18 Q957R (CGG)This studyAddgene Plasmid ID 212414pTwist-SARS-CoV-2 Spike-ΔC18 B.1.526v1This studyAddgene Plasmid ID 212415pTwist-SARS-CoV-2 Spike-ΔC18 B.1.526v2This studyAddgene Plasmid ID 212416pTwist-SARS-CoV-2 Spike-ΔC18 T19R (AGA)This studyAddgene Plasmid ID 212417pTwist-SARS-CoV-2 Spike-ΔC18 K77T (ACG)This studyAddgene Plasmid ID 212418pTwist-SARS-CoV-2 Spike-ΔC18 G142D (GAT)This studyAddgene Plasmid ID 212419pTwist-SARS-CoV-2 Spike-ΔC18 E154K (AAA)This studyAddgene Plasmid ID 212420pTwist-SARS-CoV-2 Spike-ΔC18 ΔE156-F157 + R158G (GGA)This studyAddgene Plasmid ID 212421pTwist-SARS-CoV-2 Spike-ΔC18 T478K (AAA)This studyAddgene Plasmid ID 212422pTwist-SARS-CoV-2 Spike-ΔC18 E484Q (CAA)This studyAddgene Plasmid ID 212423pTwist-SARS-CoV-2 Spike-ΔC18 P681R (CGT)This studyAddgene Plasmid ID 212424pTwist-SARS-CoV-2 Spike-ΔC18 D950N (AAT)This studyAddgene Plasmid ID 212425pTwist-SARS-CoV-2 Spike-ΔC18 Q1071H (CAT)This studyAddgene Plasmid ID 212426pTwist-SARS-CoV-2 Spike-ΔC18 H1101D (GAC)This studyAddgene Plasmid ID 212427pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v1 (B.1.617.1 v1)This studyAddgene Plasmid ID 212428pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v2 (B.1.617.1 v2)This studyAddgene Plasmid ID 212429pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v3 (B.1.617.2 v2)This studyAddgene Plasmid ID 212430pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v4 (B.1.617.2 v1)This studyAddgene Plasmid ID 212431pTwist-SARS-CoV-2 Spike-ΔC18 V70F (TTT)This studyAddgene Plasmid ID 212432pTwist-SARS-CoV-2 Spike-ΔC18 W258L (CTG)This studyAddgene Plasmid ID 212433pTwist-SARS-CoV-2 Spike-ΔC18 AY.1This studyAddgene Plasmid ID 212434pTwist-SARS-CoV-2 Spike-ΔC18 AY.2This studyAddgene Plasmid ID 212435pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT)This studyAddgene Plasmid ID 212436pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) T478K (AAA)This studyAddgene Plasmid ID 212437pTwist-SARS-CoV-2 Spike-ΔC18 L452R (CGT) T478K (AAA)This studyAddgene Plasmid ID 212438pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA)This studyAddgene Plasmid ID 212439pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA) E484K (AAA)This studyAddgene Plasmid ID 212440pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA) E484Q (CAA)This studyAddgene Plasmid ID 212441pTwist-SARS-CoV-2 Spike-ΔC18 G75V (GTA)This studyAddgene Plasmid ID 212442pTwist-SARS-CoV-2 Spike-ΔC18 T76I (ATT)This studyAddgene Plasmid ID 212443pTwist-SARS-CoV-2 Spike-ΔC18 G75V (GTA) T76I (ATT)This studyAddgene Plasmid ID 212444pTwist-SARS-CoV-2 Spike-ΔC18 ΔR246-G252 + D253N (AAC)This studyAddgene Plasmid ID 212445pTwist-SARS-CoV-2 Spike-ΔC18 L452Q (CAA)This studyAddgene Plasmid ID 212446pTwist-SARS-CoV-2 Spike-ΔC18 F490S (TCT)This studyAddgene Plasmid ID 212447pTwist-SARS-CoV-2 Spike-ΔC18 T859N (AAC)This studyAddgene Plasmid ID 212448pTwist-SARS-CoV-2 Spike-ΔC18 C.37This studyAddgene Plasmid ID 212449pTwist-SARS-CoV-2 Spike-ΔC18 L452Q (CAA) F490S (TCT)This studyAddgene Plasmid ID 212450pTwist-SARS-CoV-2 Spike-ΔC18 YY144TSN (ACTTCTAAC)This studyAddgene Plasmid ID 212451pTwist-SARS-CoV-2 Spike-ΔC18 R346K (AAA)This studyAddgene Plasmid ID 212452pTwist-SARS-CoV-2 Spike-ΔC18 B.1.621 (Mu)This studyAddgene Plasmid ID 212453pTwist-SARS-CoV-2 Spike-ΔC18 G339HThis studyAddgene Plasmid ID 212454pTwist-SARS-CoV-2 Spike-ΔC18 EG.5.1This studyAddgene Plasmid ID 212455pTwist-SARS-CoV-2 Spike-ΔC18 Y145H (CAT)This studyAddgene Plasmid ID 212456pTwist-SARS-CoV-2 Spike-ΔC18 AY.4.2This studyAddgene Plasmid ID 212457pTwist-SARS-CoV-2 Spike-ΔC18 ΔV143-Y145This studyAddgene Plasmid ID 212458pTwist-SARS-CoV-2 Spike-ΔC18 G142D (GAT)+ΔV143-Y145This studyAddgene Plasmid ID 212459pTwist-SARS-CoV-2 Spike-ΔC18 N211I (ATT)+ΔL212This studyAddgene Plasmid ID 212460pTwist-SARS-CoV-2 Spike-ΔC18 InsertionR214-EPEThis studyAddgene Plasmid ID 212461pTwist-SARS-CoV-2 Spike-ΔC18 N211I (ATT) ΔL212+InsertionR214-EPEThis studyAddgene Plasmid ID 212462pTwist-SARS-CoV-2 Spike-ΔC18 G339D (GAT)This studyAddgene Plasmid ID 212463pTwist-SARS-CoV-2 Spike-ΔC18 S371L (CTC)This studyAddgene Plasmid ID 212464pTwist-SARS-CoV-2 Spike-ΔC18 S373P (CCA)This studyAddgene Plasmid ID 212465pTwist-SARS-CoV-2 Spike-ΔC18 S375F (TTC)This studyAddgene Plasmid ID 212466pTwist-SARS-CoV-2 Spike-ΔC18 S371L (CTC) S373P (CCA) S375F (TTC)This studyAddgene Plasmid ID 212467pTwist-SARS-CoV-2 Spike-ΔC18 G446S (AGC)This studyAddgene Plasmid ID 212468pTwist-SARS-CoV-2 Spike-ΔC18 N440K (AAG) G446S (AGC)This studyAddgene Plasmid ID 212469pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC) T478K (AAA)This studyAddgene Plasmid ID 212470pTwist-SARS-CoV-2 Spike-ΔC18 E484A (GCA)This studyAddgene Plasmid ID 212471pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC) T478K (AAA) E484A (GCA)This studyAddgene Plasmid ID 212472pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA)This studyAddgene Plasmid ID 212473pTwist-SARS-CoV-2 Spike-ΔC18 G496S (TCA)This studyAddgene Plasmid ID 212474pTwist-SARS-CoV-2 Spike-ΔC18 Q498R (CGA)This studyAddgene Plasmid ID 212475pTwist-SARS-CoV-2 Spike-ΔC18 Y505H (CAT)This studyAddgene Plasmid ID 212476pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA) G496S (TCA) Q498R (CGA) N501Y (TAT) Y505H (CAT)This studyAddgene Plasmid ID 212477pTwist-SARS-CoV-2 Spike-ΔC18 T547K (AAA)This studyAddgene Plasmid ID 212478pTwist-SARS-CoV-2 Spike-ΔC18 N679K (AAA)This studyAddgene Plasmid ID 212479pTwist-SARS-CoV-2 Spike-ΔC18 N679K (AAA) P681H (CAC)This studyAddgene Plasmid ID 212480pTwist-SARS-CoV-2 Spike-ΔC18 N764K (AAA)This studyAddgene Plasmid ID 212481pTwist-SARS-CoV-2 Spike-ΔC18 D796Y (TAT)This studyAddgene Plasmid ID 212482pTwist-SARS-CoV-2 Spike-ΔC18 N856K (AAG)This studyAddgene Plasmid ID 212483pTwist-SARS-CoV-2 Spike-ΔC18 Q954H (CAC)This studyAddgene Plasmid ID 212484pTwist-SARS-CoV-2 Spike-ΔC18 N969K (AAA)This studyAddgene Plasmid ID 212485pTwist-SARS-CoV-2 Spike-ΔC18 L981F (TTC)This studyAddgene Plasmid ID 212486pTwist-SARS-CoV-2 Spike-ΔC18 BA.2This studyAddgene Plasmid ID 212487pTwist-SARS-CoV-2 Spike-ΔC18 T19I (ATA)This studyAddgene Plasmid ID 212488pTwist-SARS-CoV-2 Spike-ΔC18 ΔL24P25P26 A27S (TCT)This studyAddgene Plasmid ID 212489pTwist-SARS-CoV-2 Spike-ΔC18 V213G (GGT)This studyAddgene Plasmid ID 212490pTwist-SARS-CoV-2 Spike-ΔC18 S371F (TTC)This studyAddgene Plasmid ID 212491pTwist-SARS-CoV-2 Spike-ΔC18 T376A (GCT)This studyAddgene Plasmid ID 212492pTwist-SARS-CoV-2 Spike-ΔC18 S371F (TTC) S373P (CCA) S375F (TTC) T376A (GCT)This studyAddgene Plasmid ID 212493pTwist-SARS-CoV-2 Spike-ΔC18 D405N (AAC)This studyAddgene Plasmid ID 212494pTwist-SARS-CoV-2 Spike-ΔC18 R408S (AGC)This studyAddgene Plasmid ID 212495pTwist-SARS-CoV-2 Spike-ΔC18 D405N (AAC) R408S (AGC)This studyAddgene Plasmid ID 212496pTwist-SARS-CoV-2 Spike-ΔC18 N440K (AAG)This studyAddgene Plasmid ID 212497pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA) Q498R (CGA) N501Y (TAT) Y505H (CAT)This studyAddgene Plasmid ID 212498pTwist-SARS-CoV-2 Spike-ΔC18 Q954H (CAT)This studyAddgene Plasmid ID 212499pTwist-SARS-CoV-2 Spike-ΔC18 V3G (GGT)This studyAddgene Plasmid ID 212500pTwist-SARS-CoV-2 Spike-ΔC18 F486V (GTT)This studyAddgene Plasmid ID 212501pTwist-SARS-CoV-2 Spike-ΔC18 S704L (TTA)This studyAddgene Plasmid ID 212502pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.12.1This studyAddgene Plasmid ID 212503pTwist-SARS-CoV-2 Spike-ΔC18 BA.4 + V3GThis studyAddgene Plasmid ID 212504pTwist-SARS-CoV-2 Spike-ΔC18 BA.5This studyAddgene Plasmid ID 212505pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.75This studyAddgene Plasmid ID 212506pTwist-SARS-CoV-2 Spike-ΔC18 BQ.1.1This studyAddgene Plasmid ID 212507pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.75.2This studyAddgene Plasmid ID 212508pTwist-SARS-CoV-2 Spike-ΔC18 R346T(ACA)This studyAddgene Plasmid ID 212509pTwist-SARS-CoV-2 Spike-ΔC18 N460K(AAG)This studyAddgene Plasmid ID 212510pTwist-SARS-CoV-2 Spike-ΔC18 K444T(ACA)This studyAddgene Plasmid ID 212511pTwist-SARS-CoV-2 Spike-ΔC18 F486S(TCT)This studyAddgene Plasmid ID 212512pTwist-SARS-CoV-2 Spike-ΔC18 D1199N(AAC)This studyAddgene Plasmid ID 212513pTwist-SARS-CoV-2 Spike-ΔC18 W152R(CGG)This studyAddgene Plasmid ID 212514pTwist-SARS-CoV-2 Spike-ΔC18 F157L(TTA)This studyAddgene Plasmid ID 212515pTwist-SARS-CoV-2 Spike-ΔC18 K147E(GAG)This studyAddgene Plasmid ID 212516pTwist-SARS-CoV-2 Spike-ΔC18 I210V(GTA)This studyAddgene Plasmid ID 212517pTwist-SARS-CoV-2 Spike-ΔC18 G257S(AGT)This studyAddgene Plasmid ID 212518pTwist-SARS-CoV-2 Spike-ΔC18 BA.4This studyAddgene Plasmid ID 212519pTwist-SARS-CoV-2 Spike-ΔC18 BQ.1.1.22 (ΔY144)This studyAddgene Plasmid ID 212520pTwist-SARS-CoV-2 Spike-ΔC18 XBBThis studyAddgene Plasmid ID 212521pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1This studyAddgene Plasmid ID 212522pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1.5This studyAddgene Plasmid ID 212523pTwist-SARS-CoV-2 Spike-ΔC18 V83AThis studyAddgene Plasmid ID 212524pTwist-SARS-CoV-2 Spike-ΔC18 H146QThis studyAddgene Plasmid ID 212525pTwist-SARS-CoV-2 Spike-ΔC18 Q183EThis studyAddgene Plasmid ID 212526pTwist-SARS-CoV-2 Spike-ΔC18 V213EThis studyAddgene Plasmid ID 212527pTwist-SARS-CoV-2 Spike-ΔC18 G252VThis studyAddgene Plasmid ID 212528pTwist-SARS-CoV-2 Spike-ΔC18 L368IThis studyAddgene Plasmid ID 212529pTwist-SARS-CoV-2 Spike-ΔC18 V445PThis studyAddgene Plasmid ID 212530pTwist-SARS-CoV-2 Spike-ΔC18 F486PThis studyAddgene Plasmid ID 212531pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1.16This studyAddgene Plasmid ID 212532pTwist-SARS-CoV-2 Spike-ΔC18 T478R (AGA)This studyAddgene Plasmid ID 212533pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1 T478RThis studyAddgene Plasmid ID 212534pTwist-SARS-CoV-2 Spike-ΔC18 HK.3This studyAddgene Plasmid ID 212572pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.86This studyAddgene Plasmid ID 212538pTwist-SARS-CoV-2 Spike-ΔC18 JN.1This studyAddgene Plasmid ID 216526pTwist-SARS-CoV-2 Spike-ΔC18 KP.2This studyAddgene Plasmid ID 223273pTwist-SARS-CoV-2 Spike-ΔC18 KP.3This studyAddgene Plasmid ID 223276pHDM-Hgpm2 (Gag-Pol)This studyAddgene Plasmid ID 164441pHDM-Tat1b (helper)This studyAddgene Plasmid ID 164442pRC-CMV-Rev1b (helper)This studyAddgene Plasmid ID164443Software and algorithmsGraphPad Prism 9.4.158Graphpad Softwarewww.graphpad.com/scientific-software/prism/; RRID:SCR_002798Geneious Prime 2023Geneioushttp://www.geneious.com/; RRID:SCR_010519FlowJo 10FlowJohttps://www.flowjo.com; RRID:SCR_008520Fluent ControlTecanhttps://lifesciences.tecan.com/fluent-laboratory-automation-workstation?p=tab--4R v2023.06.1 + 524Open source softwarehttps://cran.r-project.org/bin/windows/base/; RRID:SCR_001905CellCapTureStratedigmhttps://stratedigm.com/cellcapture/QuantStudio 12K Software v1.3Applied Bioscienceshttps://www.thermofisher.com/us/en/home/global/forms/quantstudio-12k-flex-software-download.html REAGENT or RESOURCESOURCEIDENTIFIERBacterial and virus strainsDH5α Zymo-Competent E. coliZymoCat# T3009Chemicals, peptides, and recombinant proteinsPhosphate buffered saline (PBS)CorningCat# 21-031-CVDulbecco’s modified eagle medium (DMEM)CorningCat# 10-013-CVFetal bovine serum (FBS)VWRCat# 89510-186Paraformaldehyde Solution, 4% in PBS, Affymetrix/USB™Fisher ScientificCat# AAJ19943K2Penicillin/streptomycinCorningCat# 30-002-CIPolyethylenimine 25K MW, linearPolysciences IncCat# 23966PuromycinSigmaCat# P8833-10MGATPSigmaCat# A2383-5GMagnesium chlorideBDHCat# BDH9244-500GMagnesium sulfateBDHCat# BDH9246-500GDithiothreitol (DTT)VWRCat# 97061-338D-luciferinGold BioCat# LUCK-2GEDTASigmaCat# 03690-100MLTriton X-100FisherCat# BP151-500PolybreneSigmaCat# H9268-5GqScript XLT 1-Step RT-qPCR ToughMix, Low-ROXQuantabioCat# 95134-500Turbo DNaseFisherCat# AM2239Recombinant Human ACE-2 His-tag Alexa Fluor® 647 ProteinR&D SystemsCat# AFR933Experimental models: Cell linesHEK293T/17 CellsATCCCat# CRL-11268293T/ACE2.MFObtained from the lab of Dr. Michael FarzanN/AOligonucleotidesLentivirus LTR qPCR Probe/56-FAM/AGC+C/i5NitInd/GG + GA/ZEN/GCTCTCTGGC/3IABkFQ/Integrated DNA TechnologyN/ALentivirus LTR qPCR 5′ Primer GGTCTCTCTIGITAGACCAGIntegrated DNA TechnologyN/ALentivirus LTR qPCR 3′ Primer TTTATTGAGGCTTAAGCAGTGGGIntegrated DNA TechnologyN/ARecombinant DNApHAGE-CMV-Luc2-IRES-ZsGreen-W (backbone)This studyAddgene Plasmid ID 164432pTwist-SARS-CoV-2 Δ18 (spike)This studyAddgene Plasmid ID 164436pTwist-SARS-CoV-2 Δ18 B.1.617.2v1 (spike)This studyAddgene Plasmid ID 179905pTwist-SARS-CoV-2 Δ18 B.1.351v2 (spike)This studyAddgene Plasmid ID 169463pTwist-SARS-CoV-2 Δ18 P.1 (spike)This studyAddgene Plasmid ID 173476pTwist-SARS-CoV-2 Δ18 B.1.1.529 (spike)This studyAddgene Plasmid ID 179906pTwist-SARS-CoV-2 Spike-ΔC18 A222V (GTG)This studyAddgene Plasmid ID 212329pTwist-SARS-CoV-2 Spike-ΔC18 D253G (GGC)This studyAddgene Plasmid ID 212330pTwist-SARS-CoV-2 Spike-ΔC18 E281V (GTA)This studyAddgene Plasmid ID 212331pTwist-SARS-CoV-2 Spike-ΔC18 N439K (AAA)This studyAddgene Plasmid ID 212332pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC)This studyAddgene Plasmid ID 212333pTwist-SARS-CoV-2 Spike-ΔC18 D936Y (TAT)This studyAddgene Plasmid ID 212334pTwist-SARS-CoV-2 Spike-ΔC18 L5F (TTC)This studyAddgene Plasmid ID 212335pTwist-SARS-CoV-2 Spike-ΔC18 ΔH69V70This studyAddgene Plasmid ID 212336pTwist-SARS-CoV-2 Spike-ΔC18 ΔY145This studyAddgene Plasmid ID 212337pTwist-SARS-CoV-2 Spike-ΔC18 N501Y (TAT)This studyAddgene Plasmid ID 212338pTwist-SARS-CoV-2 Spike-ΔC18 A570D (GAC)This studyAddgene Plasmid ID 212339pTwist-SARS-CoV-2 Spike-ΔC18 P681H (CAC)This studyAddgene Plasmid ID 212340pTwist-SARS-CoV-2 Spike-ΔC18 T716I (ATT)This studyAddgene Plasmid ID 212341pTwist-SARS-CoV-2 Spike-ΔC18 S982A (GCC)This studyAddgene Plasmid ID 212342pTwist-SARS-CoV-2 Spike-ΔC18 D1118H (CAC)This studyAddgene Plasmid ID 212343pTwist-SARS-CoV-2 Spike-ΔC18 D80A (GCT)This studyAddgene Plasmid ID 212344pTwist-SARS-CoV-2 Spike-ΔC18 D215G (GGT)This studyAddgene Plasmid ID 212345pTwist-SARS-CoV-2 Spike-ΔC18 L242H (CAT)This studyAddgene Plasmid ID 212346pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT)This studyAddgene Plasmid ID 212347pTwist-SARS-CoV-2 Spike-ΔC18 E484K (AAA)This studyAddgene Plasmid ID 212348pTwist-SARS-CoV-2 Spike-ΔC18 A701V (GTT)This studyAddgene Plasmid ID 212349pTwist-SARS-CoV-2 Spike-ΔC18 SAK005321 (Wrong L242H)This studyAddgene Plasmid ID 212350pTwist-SARS-CoV-2 Spike-ΔC18 V1176F (TTC)This studyAddgene Plasmid ID 212351pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) E484K (AAA)This studyAddgene Plasmid ID 212352pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) N501Y (TAT)This studyAddgene Plasmid ID 212353pTwist-SARS-CoV-2 Spike-ΔC18 E484K (AAA) N501Y (TAT)This studyAddgene Plasmid ID 212354pTwist-SARS-CoV-2 Spike-ΔC18 ΔL242-L244This studyAddgene Plasmid ID 212355pTwist-SARS-CoV-2 Spike-ΔC18 R246I (ATA)This studyAddgene Plasmid ID 212356pTwist-SARS-CoV-2 Spike-ΔC18 ΔL242-L244 + R246I (ATA)This studyAddgene Plasmid ID 212357pTwist-SARS-CoV-2 Spike-ΔC18 L18F (TTC)This studyAddgene Plasmid ID 212358pTwist-SARS-CoV-2 Spike-ΔC18 T20N (AAT)This studyAddgene Plasmid ID 212359pTwist-SARS-CoV-2 Spike-ΔC18 P26S (TCC)This studyAddgene Plasmid ID 212360pTwist-SARS-CoV-2 Spike-ΔC18 D138Y (TAT)This studyAddgene Plasmid ID 212361pTwist-SARS-CoV-2 Spike-ΔC18 R190S (AGC)This studyAddgene Plasmid ID 212362pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG)This studyAddgene Plasmid ID 212363pTwist-SARS-CoV-2 Spike-ΔC18 H655Y (TAT)This studyAddgene Plasmid ID 212364pTwist-SARS-CoV-2 Spike-ΔC18 T1027I (ATT)This studyAddgene Plasmid ID 212365pTwist-SARS-CoV-2 Spike-ΔC18 S13I (ATC)This studyAddgene Plasmid ID 2123662971 - pTwist-SARS-CoV-2 Spike-ΔC18 W152C (TGC)This studyAddgene Plasmid ID 212367pTwist-SARS-CoV-2 Spike-ΔC18 L452R (CGT)This studyAddgene Plasmid ID 212368pTwist-SARS-CoV-2 Spike-ΔC18 Y453F (TTC)This studyAddgene Plasmid ID 212369pTwist-SARS-CoV-2 Spike-ΔC18 I692V (GTA)This studyAddgene Plasmid ID 212370pTwist-SARS-CoV-2 Spike-ΔC18 M1229I (ATC)This studyAddgene Plasmid ID 212371pTwist-SARS-CoV-2 Spike-ΔC18 Danish Mink ΔFVIThis studyAddgene Plasmid ID 212372pTwist-SARS-CoV-2 Spike-ΔC18 T307I (ATA)This studyAddgene Plasmid ID 212373pTwist-SARS-CoV-2 Spike-ΔC18 T572I (ATC)This studyAddgene Plasmid ID 212374pTwist-SARS-CoV-2 Spike-ΔC18 Q239R (CGA)This studyAddgene Plasmid ID 212375pTwist-SARS-CoV-2 Spike-ΔC18 Q677H (CAT)This studyAddgene Plasmid ID 212376pTwist-SARS-CoV-2 Spike-ΔC18 T307I (ATA) T572I (ATC) D614G (GGT)This studyAddgene Plasmid ID 212377pTwist-SARS-CoV-2 Spike-ΔC18 Q239R (CGA) D614G (GGT)This studyAddgene Plasmid ID 212378pTwist-SARS-CoV-2 Spike-ΔC18 D614G (GGT) Q677H (CAT) D936Y (TAT)This studyAddgene Plasmid ID 212379pTwist-SARS-CoV-2 Spike-ΔC18 SAK006840 VOC-501Y.V2 (B.1.351v3) - No RBD MutationsThis studyAddgene Plasmid ID 212380pTwist-SARS-CoV-2 Spike-ΔC18 VOC-501Y.V2 (B.1.351) - All MutationsThis studyAddgene Plasmid ID 212381pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG) E484K (AAA)This studyAddgene Plasmid ID 212382pTwist-SARS-CoV-2 Spike-ΔC18 K417T (ACG) N501Y (TAT)This studyAddgene Plasmid ID 212383pTwist-SARS-CoV-2 Spike-ΔC18 (P.1) - No RBD MutationsThis studyAddgene Plasmid ID 212384pTwist-SARS-CoV-2 Spike-ΔC18 (P.2/B.1.1.248) - No RBD MutationsThis studyAddgene Plasmid ID 212385pTwist-SARS-CoV-2 Spike-ΔC18 R683G (GGC)This studyAddgene Plasmid ID 212386pTwist-SARS-CoV-2 Spike-ΔC18 SA501.V2 (Triple RBD) R683G (GGC)This studyAddgene Plasmid ID 212387pTwist-SARS-CoV-2 Spike-ΔC18 VOC-501Y.V2 (B.1.351) - McGuire MutationsThis studyAddgene Plasmid ID 212388pTwist-SARS-CoV-2 Spike-ΔC18 SA190 VOC-501Y.V2 (B.1.351v4)This studyAddgene Plasmid ID 212389pTwist-SARS-CoV-2 Spike-ΔC18 D215H (CAT)This studyAddgene Plasmid ID 212390pTwist-SARS-CoV-2 Spike-ΔC18 SAK006879 VOC-501Y.V2 (B.1.351v5)This studyAddgene Plasmid ID 212391pTwist-SARS-CoV-2 Spike-ΔC18 A27S (TCT)This studyAddgene Plasmid ID 212392pTwist-SARS-CoV-2 Spike-ΔC18 SAK007134 VOC-501Y.V2 (B.1.351v6)This studyAddgene Plasmid ID 212393pTwist-SARS-CoV-2 Spike-ΔC18 Q52R (CGA)This studyAddgene Plasmid ID 212394pTwist-SARS-CoV-2 Spike-ΔC18 A67V (GTT)This studyAddgene Plasmid ID 212395pTwist-SARS-CoV-2 Spike-ΔC18 A67V (GTT) + ΔH69V70This studyAddgene Plasmid ID 212396pTwist-SARS-CoV-2 Spike-ΔC18 F888L (CTT)This studyAddgene Plasmid ID 212397pTwist-SARS-CoV-2 Spike-ΔC18 (B.1.525)This studyAddgene Plasmid ID 212398pTwist-SARS-CoV-2 Spike-ΔC18 (Robin)This studyAddgene Plasmid ID 212399pTwist-SARS-CoV-2 Spike-ΔC18 Q677P (CCA)This studyAddgene Plasmid ID 212400pTwist-SARS-CoV-2 Spike-ΔC18 (Pelican)This studyAddgene Plasmid ID 212401pTwist-SARS-CoV-2 Spike-ΔC18 (Yellowhammer)This studyAddgene Plasmid ID 212402pTwist-SARS-CoV-2 Spike-ΔC18 T29I (ATA)This studyAddgene Plasmid ID 212403pTwist-SARS-CoV-2 Spike-ΔC18 T572I (ATC)This studyAddgene Plasmid ID 212404pTwist-SARS-CoV-2 Spike-ΔC18 D936N (AAT)This studyAddgene Plasmid ID 212405pTwist-SARS-CoV-2 Spike-ΔC18 (Bluebird)This studyAddgene Plasmid ID 212406pTwist-SARS-CoV-2 Spike-ΔC18 T732S (AGT)This studyAddgene Plasmid ID 212407pTwist-SARS-CoV-2 Spike-ΔC18 (Quail)This studyAddgene Plasmid ID 212408pTwist-SARS-CoV-2 Spike-ΔC18 G142S (AGC)This studyAddgene Plasmid ID 212409pTwist-SARS-CoV-2 Spike-ΔC18 E180V (GTA)This studyAddgene Plasmid ID 212410pTwist-SARS-CoV-2 Spike-ΔC18 (Mockingbird)This studyAddgene Plasmid ID 212411pTwist-SARS-CoV-2 Spike-ΔC18 (P.1) Triple RBDThis studyAddgene Plasmid ID 212412pTwist-SARS-CoV-2 Spike-ΔC18 T95I (ATA)This studyAddgene Plasmid ID 212413pTwist-SARS-CoV-2 Spike-ΔC18 Q957R (CGG)This studyAddgene Plasmid ID 212414pTwist-SARS-CoV-2 Spike-ΔC18 B.1.526v1This studyAddgene Plasmid ID 212415pTwist-SARS-CoV-2 Spike-ΔC18 B.1.526v2This studyAddgene Plasmid ID 212416pTwist-SARS-CoV-2 Spike-ΔC18 T19R (AGA)This studyAddgene Plasmid ID 212417pTwist-SARS-CoV-2 Spike-ΔC18 K77T (ACG)This studyAddgene Plasmid ID 212418pTwist-SARS-CoV-2 Spike-ΔC18 G142D (GAT)This studyAddgene Plasmid ID 212419pTwist-SARS-CoV-2 Spike-ΔC18 E154K (AAA)This studyAddgene Plasmid ID 212420pTwist-SARS-CoV-2 Spike-ΔC18 ΔE156-F157 + R158G (GGA)This studyAddgene Plasmid ID 212421pTwist-SARS-CoV-2 Spike-ΔC18 T478K (AAA)This studyAddgene Plasmid ID 212422pTwist-SARS-CoV-2 Spike-ΔC18 E484Q (CAA)This studyAddgene Plasmid ID 212423pTwist-SARS-CoV-2 Spike-ΔC18 P681R (CGT)This studyAddgene Plasmid ID 212424pTwist-SARS-CoV-2 Spike-ΔC18 D950N (AAT)This studyAddgene Plasmid ID 212425pTwist-SARS-CoV-2 Spike-ΔC18 Q1071H (CAT)This studyAddgene Plasmid ID 212426pTwist-SARS-CoV-2 Spike-ΔC18 H1101D (GAC)This studyAddgene Plasmid ID 212427pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v1 (B.1.617.1 v1)This studyAddgene Plasmid ID 212428pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v2 (B.1.617.1 v2)This studyAddgene Plasmid ID 212429pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v3 (B.1.617.2 v2)This studyAddgene Plasmid ID 212430pTwist-SARS-CoV-2 Spike-ΔC18 B.1.617v4 (B.1.617.2 v1)This studyAddgene Plasmid ID 212431pTwist-SARS-CoV-2 Spike-ΔC18 V70F (TTT)This studyAddgene Plasmid ID 212432pTwist-SARS-CoV-2 Spike-ΔC18 W258L (CTG)This studyAddgene Plasmid ID 212433pTwist-SARS-CoV-2 Spike-ΔC18 AY.1This studyAddgene Plasmid ID 212434pTwist-SARS-CoV-2 Spike-ΔC18 AY.2This studyAddgene Plasmid ID 212435pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT)This studyAddgene Plasmid ID 212436pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) T478K (AAA)This studyAddgene Plasmid ID 212437pTwist-SARS-CoV-2 Spike-ΔC18 L452R (CGT) T478K (AAA)This studyAddgene Plasmid ID 212438pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA)This studyAddgene Plasmid ID 212439pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA) E484K (AAA)This studyAddgene Plasmid ID 212440pTwist-SARS-CoV-2 Spike-ΔC18 K417N (AAT) L452R (CGT) T478K (AAA) E484Q (CAA)This studyAddgene Plasmid ID 212441pTwist-SARS-CoV-2 Spike-ΔC18 G75V (GTA)This studyAddgene Plasmid ID 212442pTwist-SARS-CoV-2 Spike-ΔC18 T76I (ATT)This studyAddgene Plasmid ID 212443pTwist-SARS-CoV-2 Spike-ΔC18 G75V (GTA) T76I (ATT)This studyAddgene Plasmid ID 212444pTwist-SARS-CoV-2 Spike-ΔC18 ΔR246-G252 + D253N (AAC)This studyAddgene Plasmid ID 212445pTwist-SARS-CoV-2 Spike-ΔC18 L452Q (CAA)This studyAddgene Plasmid ID 212446pTwist-SARS-CoV-2 Spike-ΔC18 F490S (TCT)This studyAddgene Plasmid ID 212447pTwist-SARS-CoV-2 Spike-ΔC18 T859N (AAC)This studyAddgene Plasmid ID 212448pTwist-SARS-CoV-2 Spike-ΔC18 C.37This studyAddgene Plasmid ID 212449pTwist-SARS-CoV-2 Spike-ΔC18 L452Q (CAA) F490S (TCT)This studyAddgene Plasmid ID 212450pTwist-SARS-CoV-2 Spike-ΔC18 YY144TSN (ACTTCTAAC)This studyAddgene Plasmid ID 212451pTwist-SARS-CoV-2 Spike-ΔC18 R346K (AAA)This studyAddgene Plasmid ID 212452pTwist-SARS-CoV-2 Spike-ΔC18 B.1.621 (Mu)This studyAddgene Plasmid ID 212453pTwist-SARS-CoV-2 Spike-ΔC18 G339HThis studyAddgene Plasmid ID 212454pTwist-SARS-CoV-2 Spike-ΔC18 EG.5.1This studyAddgene Plasmid ID 212455pTwist-SARS-CoV-2 Spike-ΔC18 Y145H (CAT)This studyAddgene Plasmid ID 212456pTwist-SARS-CoV-2 Spike-ΔC18 AY.4.2This studyAddgene Plasmid ID 212457pTwist-SARS-CoV-2 Spike-ΔC18 ΔV143-Y145This studyAddgene Plasmid ID 212458pTwist-SARS-CoV-2 Spike-ΔC18 G142D (GAT)+ΔV143-Y145This studyAddgene Plasmid ID 212459pTwist-SARS-CoV-2 Spike-ΔC18 N211I (ATT)+ΔL212This studyAddgene Plasmid ID 212460pTwist-SARS-CoV-2 Spike-ΔC18 InsertionR214-EPEThis studyAddgene Plasmid ID 212461pTwist-SARS-CoV-2 Spike-ΔC18 N211I (ATT) ΔL212+InsertionR214-EPEThis studyAddgene Plasmid ID 212462pTwist-SARS-CoV-2 Spike-ΔC18 G339D (GAT)This studyAddgene Plasmid ID 212463pTwist-SARS-CoV-2 Spike-ΔC18 S371L (CTC)This studyAddgene Plasmid ID 212464pTwist-SARS-CoV-2 Spike-ΔC18 S373P (CCA)This studyAddgene Plasmid ID 212465pTwist-SARS-CoV-2 Spike-ΔC18 S375F (TTC)This studyAddgene Plasmid ID 212466pTwist-SARS-CoV-2 Spike-ΔC18 S371L (CTC) S373P (CCA) S375F (TTC)This studyAddgene Plasmid ID 212467pTwist-SARS-CoV-2 Spike-ΔC18 G446S (AGC)This studyAddgene Plasmid ID 212468pTwist-SARS-CoV-2 Spike-ΔC18 N440K (AAG) G446S (AGC)This studyAddgene Plasmid ID 212469pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC) T478K (AAA)This studyAddgene Plasmid ID 212470pTwist-SARS-CoV-2 Spike-ΔC18 E484A (GCA)This studyAddgene Plasmid ID 212471pTwist-SARS-CoV-2 Spike-ΔC18 S477N (AAC) T478K (AAA) E484A (GCA)This studyAddgene Plasmid ID 212472pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA)This studyAddgene Plasmid ID 212473pTwist-SARS-CoV-2 Spike-ΔC18 G496S (TCA)This studyAddgene Plasmid ID 212474pTwist-SARS-CoV-2 Spike-ΔC18 Q498R (CGA)This studyAddgene Plasmid ID 212475pTwist-SARS-CoV-2 Spike-ΔC18 Y505H (CAT)This studyAddgene Plasmid ID 212476pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA) G496S (TCA) Q498R (CGA) N501Y (TAT) Y505H (CAT)This studyAddgene Plasmid ID 212477pTwist-SARS-CoV-2 Spike-ΔC18 T547K (AAA)This studyAddgene Plasmid ID 212478pTwist-SARS-CoV-2 Spike-ΔC18 N679K (AAA)This studyAddgene Plasmid ID 212479pTwist-SARS-CoV-2 Spike-ΔC18 N679K (AAA) P681H (CAC)This studyAddgene Plasmid ID 212480pTwist-SARS-CoV-2 Spike-ΔC18 N764K (AAA)This studyAddgene Plasmid ID 212481pTwist-SARS-CoV-2 Spike-ΔC18 D796Y (TAT)This studyAddgene Plasmid ID 212482pTwist-SARS-CoV-2 Spike-ΔC18 N856K (AAG)This studyAddgene Plasmid ID 212483pTwist-SARS-CoV-2 Spike-ΔC18 Q954H (CAC)This studyAddgene Plasmid ID 212484pTwist-SARS-CoV-2 Spike-ΔC18 N969K (AAA)This studyAddgene Plasmid ID 212485pTwist-SARS-CoV-2 Spike-ΔC18 L981F (TTC)This studyAddgene Plasmid ID 212486pTwist-SARS-CoV-2 Spike-ΔC18 BA.2This studyAddgene Plasmid ID 212487pTwist-SARS-CoV-2 Spike-ΔC18 T19I (ATA)This studyAddgene Plasmid ID 212488pTwist-SARS-CoV-2 Spike-ΔC18 ΔL24P25P26 A27S (TCT)This studyAddgene Plasmid ID 212489pTwist-SARS-CoV-2 Spike-ΔC18 V213G (GGT)This studyAddgene Plasmid ID 212490pTwist-SARS-CoV-2 Spike-ΔC18 S371F (TTC)This studyAddgene Plasmid ID 212491pTwist-SARS-CoV-2 Spike-ΔC18 T376A (GCT)This studyAddgene Plasmid ID 212492pTwist-SARS-CoV-2 Spike-ΔC18 S371F (TTC) S373P (CCA) S375F (TTC) T376A (GCT)This studyAddgene Plasmid ID 212493pTwist-SARS-CoV-2 Spike-ΔC18 D405N (AAC)This studyAddgene Plasmid ID 212494pTwist-SARS-CoV-2 Spike-ΔC18 R408S (AGC)This studyAddgene Plasmid ID 212495pTwist-SARS-CoV-2 Spike-ΔC18 D405N (AAC) R408S (AGC)This studyAddgene Plasmid ID 212496pTwist-SARS-CoV-2 Spike-ΔC18 N440K (AAG)This studyAddgene Plasmid ID 212497pTwist-SARS-CoV-2 Spike-ΔC18 Q493R (CGA) Q498R (CGA) N501Y (TAT) Y505H (CAT)This studyAddgene Plasmid ID 212498pTwist-SARS-CoV-2 Spike-ΔC18 Q954H (CAT)This studyAddgene Plasmid ID 212499pTwist-SARS-CoV-2 Spike-ΔC18 V3G (GGT)This studyAddgene Plasmid ID 212500pTwist-SARS-CoV-2 Spike-ΔC18 F486V (GTT)This studyAddgene Plasmid ID 212501pTwist-SARS-CoV-2 Spike-ΔC18 S704L (TTA)This studyAddgene Plasmid ID 212502pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.12.1This studyAddgene Plasmid ID 212503pTwist-SARS-CoV-2 Spike-ΔC18 BA.4 + V3GThis studyAddgene Plasmid ID 212504pTwist-SARS-CoV-2 Spike-ΔC18 BA.5This studyAddgene Plasmid ID 212505pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.75This studyAddgene Plasmid ID 212506pTwist-SARS-CoV-2 Spike-ΔC18 BQ.1.1This studyAddgene Plasmid ID 212507pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.75.2This studyAddgene Plasmid ID 212508pTwist-SARS-CoV-2 Spike-ΔC18 R346T(ACA)This studyAddgene Plasmid ID 212509pTwist-SARS-CoV-2 Spike-ΔC18 N460K(AAG)This studyAddgene Plasmid ID 212510pTwist-SARS-CoV-2 Spike-ΔC18 K444T(ACA)This studyAddgene Plasmid ID 212511pTwist-SARS-CoV-2 Spike-ΔC18 F486S(TCT)This studyAddgene Plasmid ID 212512pTwist-SARS-CoV-2 Spike-ΔC18 D1199N(AAC)This studyAddgene Plasmid ID 212513pTwist-SARS-CoV-2 Spike-ΔC18 W152R(CGG)This studyAddgene Plasmid ID 212514pTwist-SARS-CoV-2 Spike-ΔC18 F157L(TTA)This studyAddgene Plasmid ID 212515pTwist-SARS-CoV-2 Spike-ΔC18 K147E(GAG)This studyAddgene Plasmid ID 212516pTwist-SARS-CoV-2 Spike-ΔC18 I210V(GTA)This studyAddgene Plasmid ID 212517pTwist-SARS-CoV-2 Spike-ΔC18 G257S(AGT)This studyAddgene Plasmid ID 212518pTwist-SARS-CoV-2 Spike-ΔC18 BA.4This studyAddgene Plasmid ID 212519pTwist-SARS-CoV-2 Spike-ΔC18 BQ.1.1.22 (ΔY144)This studyAddgene Plasmid ID 212520pTwist-SARS-CoV-2 Spike-ΔC18 XBBThis studyAddgene Plasmid ID 212521pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1This studyAddgene Plasmid ID 212522pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1.5This studyAddgene Plasmid ID 212523pTwist-SARS-CoV-2 Spike-ΔC18 V83AThis studyAddgene Plasmid ID 212524pTwist-SARS-CoV-2 Spike-ΔC18 H146QThis studyAddgene Plasmid ID 212525pTwist-SARS-CoV-2 Spike-ΔC18 Q183EThis studyAddgene Plasmid ID 212526pTwist-SARS-CoV-2 Spike-ΔC18 V213EThis studyAddgene Plasmid ID 212527pTwist-SARS-CoV-2 Spike-ΔC18 G252VThis studyAddgene Plasmid ID 212528pTwist-SARS-CoV-2 Spike-ΔC18 L368IThis studyAddgene Plasmid ID 212529pTwist-SARS-CoV-2 Spike-ΔC18 V445PThis studyAddgene Plasmid ID 212530pTwist-SARS-CoV-2 Spike-ΔC18 F486PThis studyAddgene Plasmid ID 212531pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1.16This studyAddgene Plasmid ID 212532pTwist-SARS-CoV-2 Spike-ΔC18 T478R (AGA)This studyAddgene Plasmid ID 212533pTwist-SARS-CoV-2 Spike-ΔC18 XBB.1 T478RThis studyAddgene Plasmid ID 212534pTwist-SARS-CoV-2 Spike-ΔC18 HK.3This studyAddgene Plasmid ID 212572pTwist-SARS-CoV-2 Spike-ΔC18 BA.2.86This studyAddgene Plasmid ID 212538pTwist-SARS-CoV-2 Spike-ΔC18 JN.1This studyAddgene Plasmid ID 216526pTwist-SARS-CoV-2 Spike-ΔC18 KP.2This studyAddgene Plasmid ID 223273pTwist-SARS-CoV-2 Spike-ΔC18 KP.3This studyAddgene Plasmid ID 223276pHDM-Hgpm2 (Gag-Pol)This studyAddgene Plasmid ID 164441pHDM-Tat1b (helper)This studyAddgene Plasmid ID 164442pRC-CMV-Rev1b (helper)This studyAddgene Plasmid ID164443Software and algorithmsGraphPad Prism 9.4.158Graphpad Softwarewww.graphpad.com/scientific-software/prism/; RRID:SCR_002798Geneious Prime 2023Geneioushttp://www.geneious.com/; RRID:SCR_010519FlowJo 10FlowJohttps://www.flowjo.com; RRID:SCR_008520Fluent ControlTecanhttps://lifesciences.tecan.com/fluent-laboratory-automation-workstation?p=tab--4R v2023.06.1 + 524Open source softwarehttps://cran.r-project.org/bin/windows/base/; RRID:SCR_001905CellCapTureStratedigmhttps://stratedigm.com/cellcapture/QuantStudio 12K Software v1.3Applied Bioscienceshttps://www.thermofisher.com/us/en/home/global/forms/quantstudio-12k-flex-software-download.html Experimental model and study participant details Human subjects Use of human samples was approved by Partners Institutional Review Board (protocol 2020P002274) and the WCG Institutional Review Board (protocol 1316159). Serum samples from 42 vaccine recipients that received two or three doses of the BNT162b2 or mRNA-1273 vaccine were collected. For each individual, basic demographic information including age and gender as well as any relevant COVID-19 history was obtained. The current analysis is part of an ongoing study101,102 in which 29 NH residents and 7 healthcare workers (HCWs) are consented directly or through their legally authorized representative if needed and serially sampled before and after each SARS-CoV-2 vaccine dose. This analysis includes data collected between August 23, 2021, and September 8, 2022. HCWs worked at 3 NH buildings, 2 Cleveland area hospitals, and Case Western Reserve University. Residents and HCWs who received SARS-CoV-2 mRNA vaccines [(BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna)] were included, and those who received the Ad26.COV2.S (Janssen) vaccine were excluded. Participants received their first booster dose 8–9 months after the primary vaccination series, and their second booster 4 to 6 months after the first booster. We report results from blood samples obtained at time points prior to and following the two booster doses. All donor genders were self-reported and informed consent was obtained from all donors. Cell lines HEK 293T cells (ATCC) were cultured in DMEM (Corning) containing 10% fetal bovine serum (VWR), and penicillin/streptomycin (Corning) at 37°C/5% CO2. 293T-ACE2 cells were a gift from Michael Farzan (Scripps Florida) and Nir Hacohen (Broad Institute) and were cultured under the same conditions. Confirmation of ACE2 expression in 293T-ACE2 cells was done via flow cytometry. Method details Construction of variant spike expression plasmids To create variant spike expression plasmids, we performed multiple PCR fragment amplifications utilizing oligonucleotides containing each desired mutation (Integrated DNA Technology) and utilized overlapping fragment assembly to generate the full complement of mutations for each strain. PCR reactions were done with Platinum SuperFI II (Thermofisher) according to the manufacturer’s protocol for reaction size and thermocycler protocol. Importantly, we generate these mutations in the context of our previously described (Garcia-Beltran et al. 202156) codon-optimized SARS-CoV-2 spike expression plasmid harboring a deletion of the C-terminal 18 amino acids that was previously demonstrated to result in higher pseudovirus titers. Assembled fragments were inserted into NotI/XbaI digested pTwist-CMV-BetaGlobin-WPRE-Neo vector utilizing the In-Fusion HD Cloning Kit (Takara) according to the manufacturer’s protocol. In-Fusion reactions were transformed into Mix and Go DH5Alpha cells (Zymo Research) according to the manufacturer’s protocol and colonies were grown overnight at 37°C to generate plasmid DNA purified using a standard miniprep protocol (Qiagen). All resulting plasmid DNA utilized in the study was verified by whole-plasmid deep sequencing (Illumina or Primordium Labs) to confirm the presence of only the intended mutations and maxi-prepped (Macherey-Nagel) to ensure high quality, high concentrated DNA. SARS-CoV-2 pseudovirus neutralization assay To compare the neutralizing activity of vaccinee sera against coronaviruses, we produced lentiviral particles pseudotyped with different spike proteins as previously described (Garcia-Beltran et al. 202156). Briefly, pseudoviruses were produced in 293T cells by PEI transfection of a lentiviral backbone encoding CMV-Luciferase-IRES-ZsGreen as well as lentiviral helper plasmids and each spike variant expression plasmid. Following collection and filtering, production was quantified by titering via flow cytometry on 293T-ACE2 cells. Neutralization assays and readout were performed on a Fluent Automated Workstation (Tecan) liquid handler using 384-well plates (Grenier). 3-fold serial dilutions ranging from 1:12 to 1:8,748 were performed for each serum sample before adding 125–250 infectious units of pseudovirus for 1 h. Subsequently, 293T-ACE2 cells containing polybrene at 8μg/mL were added to each well and incubated at 37°C/5% CO2 for 48–60 h. Following transduction, cells were lysed using a luciferin-containing buffer103 and shaken for 5 min prior to quantitation of luciferase expression within 1 h of buffer addition using a Spectramax L luminometer (Molecular Devices) or a Pherastar with Microplate Stacker (BMG Labtech). Percent neutralization was determined by subtracting background luminescence measured in cell control wells (cells only) from sample wells and dividing by virus control wells (virus and cells only). Data was analyzed using Graphpad Prism and pNT50 values were calculated by taking the inverse of the 50% inhibitory concentration value for all samples with a neutralization value of 80% or higher at the highest concentration of serum. Titering To determine the infectious units of pseudotyped lentiviral vectors, we plated 400,000 293T-ACE2 cells per well of a 12-well plate. 24 h later, three 10-fold serial dilutions of neat pseudovirus supernatant were made in 100 μL of D10, which was then used to replace 100 μL of media on the plated cells. Cells were incubated for 48 h at 37°C/5% CO2 to allow for expression of ZsGreen reporter gene and harvested with Trypsin-EDTA (Corning). Cells were resuspended in PBS supplemented with 2% FBS (PBS+), fixed with 4% paraformaldehyde (PFA) and analyzed on a Stratedigm S1300Exi Flow Cytometer to determine the percentage of ZsGreen-expressing cells. Infectious units were calculated by determining the percentage of infected cells in wells exhibiting linear decreases in transduction and multiplying by the average number of cells per well determined at the initiation of the assay using FlowJo. At low MOI, (<10% infected cells), each transduced ZsGreen cell was assumed to represent a single infectious unit. Quantitation of pseudovirus by RT-qPCR To determine the genome copy concentration of pseudotyped lentiviral vectors, lentiviral RNA was extracted from pseudovirus supernatant using the QIAamp viral RNA mini kit (Qiagen) according to the manufacturer’s protocol. Each sample was serially diluted, and each dilution was treated with 1.2 U of Turbo DNase (Invitrogen) at 37°C for 30 min followed by heat inactivation at 75°C for 15 min 10 μL of the treated RNA was used in a 20 μL qRT-PCR reaction with the qScript XLT one-step RT-qPCR Tough Mix, low ROX mix (Quanta Biosciences), a TaqMan probe containing locked nucleic acids (/56-FAM/AGC+C/i5NitInd/GG + GA/ZEN/GCTCTCTGGC/3IABkFQ/) (IDT), and primers designed for targeting the LTR gene of NL4-3 HIV genome, from which the lentiviral vector was derived (5′-GGTCTCTCTIGITAGACCAG and 3′-TTTATTGAGGCTTAAGCAGTGGG) according to the manufacturer’s protocol. Each dilution was run in duplicate on a QuantStudio 12K Flex (Applied Biosystems). The following cycling conditions were used: 50°C for 10 min, 95°C for 3 min followed by 50 cycles of 95°C for 15 s and 60°C for 1 min. Virus titer was determined by comparison with a standard curve generated using a plasmid standard generated from serial dilution of CMV-Luciferase-IRES-ZsGreen lentiviral backbone. DNase and No DNase controls were also included at 2.5 × 108 GC/mL of the same plasmid. The range of the assay was from 2.5 × 107 GC/mL to 1.5 × 103 GC/mL. Upon analysis, the average of the three most concentrated dilutions within range of the standard were used to calculate genome copies/mL. ACE2 spike binding To determine the ACE2 binding of pseudovirus spike plasmids, each individual spike expression plasmid was co-transfected into 293Ts with a ZSgreen reporter plasmid. Cells were incubated for 48 h at 37°C/5% CO2 to allow for expression of Spike and ZsGreen reporter genes and harvested with Trypsin-EDTA (Corning). Cells were washed in PBS supplemented with 2% FBS (PBS+), and then stained with Recombinant ACE2 tagged with Alexa Fluor 647 (R&D Systems) at a 1:50 dilution for 30 min in the dark at 4°C. Cells were washed twice with PBS+ and fixed with paraformaldehyde (PFA) for 15 min at 4°C. Finally, cells were washed to remove PFA, resuspended in PBS+ and analyzed on a Stratedigm S1300Exi Flow Cytometer to determine the median fluorescence intensity of ACE2 Alexa Fluor 647 for spike+ (ZSgreen+) cells. Quantification and statistical analysis Data and statistical analyses were performed using GraphPad Prism 9.0.1, and R v4.0.2. Flow cytometry data was analyzed using FlowJo 10.7.1. For all figures statistical significance was defined by GraphPad Prism as ∗ = p < 0.0332, ∗∗ = p < 0.0021, ∗∗∗ = p < 0.0002, ∗∗∗∗ = p < 0.0001. Heatmaps and hierarchical clustering were performed using pheatmap package v1.0.12 in RStudio. The structure used in all figures is PDB ID 6XR8 from https://doi.org/10.1126/science.abd4251 and was chosen given its resolution of the full-length spike allowing us to map all the mutations we made onto the structure. All structures are shown on this PDB to highlight the many mutations from the WT spike and are not meant to represent structures of the variant spikes.